ADDENDUM 1: REPLACEMENT OF VERSION 1 CONTRACT …

Private Bag X828, PRETORIA, 0001. Civitas Building Cnr Thabo Sehume & Struben Streets, PRETORIA 0001 Directorate: Access to Affordable Medicines Tel: (012) 395 8130 Fax: (012) 395 8823/4

Enquiries: CPA Ref: HP06-2021SVP e-mail: [email protected]

CONTRACT NUMBER HP06-2021SVP: SUPPLY AND DELIVERY OF SMALL VOLUME PARENTERALS AND INSULIN DEVICES TO THE DEPARTMENT OF HEALTH FOR THE

PERIOD OF 01 MAY 2021 TO 30 APRIL 2024

ADDENDUM 1: REPLACEMENT OF VERSION 1 CONTRACT CIRCULAR

Please note that awards for Safeline Pharmaceuticals (Pty) Ltd and Fresenius Kabi South Africa (Pty) Ltd has been processed and included in this contract circular. Kindy replace version 1 of the Contract Circular of HP06-2021SVP with version 2, attached as Annexure A to this addendum.

Yours faithfully

K JAMALOODIEN DIRECTOR: AFFORDABLE MEDICINES DATE:

15 April 2021

mailto:[email protected]

NES TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 01 OCTOBER 2019 TO 30 SEPTEMBER 2021

health

Department: Health REPUBLIC OF SOUTH AFRICA

Private Bag X828, PRETORIA, 0001. Civitas Building Cnr Thabo Sehume & Struben Streets, PRETORIA 0001 Directorate: Affordable Medicines, Tel: (012) 395 8530 Fax: (012) 395 8823/4

Enquiries: [email protected] Ref: HP06-2021SVP

HP06-2021SVP: SUPPLY AND DELIVERY OF SMALL VOLUME PARENTERALS AND

INSULIN DEVICES TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 01 MAY 2021 TO 30 APRIL 2024

1. The attached contract circular is for your information.

2. This contract will be subject to the General Conditions of Contract issued in accordance with Chapter 16A of the Treasury Regulations published in terms of the Public Finance Management Act, 1999 (Act 1 of 1999). The Special Requirements and Conditions of Contract are supplementary to the General Conditions of Contract. Where, however, the Special Requirements and Conditions of Contract are in conflict with the General Conditions of the Contract, the Special Requirements and Conditions of Contract will prevail.

3. The bid price offered applies to the product specified e.g. price per single unit, as per specification.

4. The following provincial Departments of Health will participate in this contract:

PARTICIPANTS CONTACT PERSON TEL NO E-MAIL

Eastern Cape Mr C Dlova (047) 532-5536 [email protected]

Free State Ms M Smits (051) 411-0525 [email protected]

Gauteng Mr DS Malele (011) 628-9131 [email protected]

Kwazulu-Natal MS SB Nhlapo (035) 901-7004 [email protected]

Limpopo Mr TS Rasekele (015) 223-9065 [email protected]

Mpumalanga Mr T Moralo (013) 283-9001 [email protected]

North West Mr M Gutta (018) 384-4838 [email protected]

Northern Cape Ms E Delport (053) 830-2717 [email protected]

Western Cape Mr N Mia (021) 483-5800 [email protected]

K JAMALOODIEN DIRECTOR: AFFORDABLE MEDICINES For: DIRECTOR-GENERAL: HEALTH DATE: 15 April 2021

mailto:[email protected]

NES TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 01 OCTOBER 2019 TO 30 SEPTEMBER 2021

HP06-2021SVP: SUPPLY AND DELIVERY OF SMALL VOLUME PARENTERALS AND INSULIN DEVICES TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 01 MAY 2021 TO 30 APRIL 2024 (PAGE 2)

1. IMPORTANT GENERAL INFORMATION

1.1 Please note that two supplier codes are listed for each supplier. This is to provide for the required supplier registration on the

Central Supplier Database (CSD) at National Treasury.

1.2 Please note that the delivered price is for the unit of measure (UOM) offered. Unit of Measure, National Stock Numbers and prices

should be carefully matched when placing or executing orders.

1.3 All prices are inclusive of 15 % VAT.

1.4 All prices are on a delivered basis.

1.5 Contact persons and e-mail addresses indicated hereunder are to be used for contract enquiries and not for orders.

2. NAMES AND ADDRESSES OF CONTRACTORS AND CONTACT DETAIL

Supplier Name Supplier Code CSD Code Postal Address Contact Person

Telephone / Cellphone Number

E-mail

Abbott Laboratories South Africa (Pty) Ltd

V2150 MAAA0030395 219 Golf Club Terrace CONSTANTIA KLOOF 1709

Maxine Smith (011) 858-2379 (060) 579-7944

[email protected]

AbbVie (Pty) Ltd V3PG3 MAAA0076921 P O Box 4840 WELTEVREDEN PARK 1709

Sarona Radley (011) 831-3200 (060) 348-9941

[email protected]

Accord Healthcare (Pty) Ltd

V2MB8 MAAA0005335 Private Bag X51 RIVONIA 2128

Reslan Nagoor (011) 234-5703 (082) 494-2510

[email protected]

Actor Pharma (Pty) Ltd V2G28 MAAA0183044 P O Box 7408 HALFWAY HOUSE 1685

Malcolm Blane s (011) 312-3812 (082) 551-4010

[email protected]

Adcock Ingram Critical Care (Pty) Ltd

V4222 MAAA0010153 P O Box 6888 JOHANNESBURG 2000

Vusani Matshidza (011) 494-8129 (079) 894-7873

[email protected]

HP06-2021SVP: SUPPLY AND DELIVERY OF SMALL VOLUME PARENTERALS AND INSULIN DEVICES TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 01 MAY 2021 TO 30 APRIL 2024

(PAGE 3)



E-mail

Adcock Ingram Healthcare (Pty) Ltd

V2272 MAAA0036413 Private Bag X69 BRYANSTON 2021

Nkosinathi.Mthethwa (011) 635-0103 (072) 328-1179

[email protected]

Ascendis Pharma (Pty) Ltd V0DM6 MAAA0043637 Postnet Suite #252 Private Bag X21 BRYANSTON 2021

Marnus Sonnekus (011) 036-9600 (082) 329-8225

[email protected]

B Braun Medical (Pty) Ltd VYL89 MAAA0040832 P O Box 1787 RANDBURG 2125

Walda Van Zyl (010) 222-3000 (073) 494-8695

[email protected]

Biotech Laboratories (Pty) Ltd

VUV35 MAAA0029826 Private Bag X65 HALFWAY HOUSE 1685

Faried Dean (011) 848-3050 (082) 455-1149

[email protected]

Equity Pharmaceuticals (Pty) Ltd

V1QZ3 MAAA0007480 100 Sovereign Drive Route 21, Corporate Park Nelmapius Drive IRENE 0157

Carel Bouwer (012) 345-1747 (082) 879-8866

[email protected]

Ferring (Pty) Ltd VXY92 MAAA0005879 Route 21, Corporate Park 6 Regency Drive IRENE 0157

Martha van Zyl (012) 443-4307 (082) 565-2656

[email protected] [email protected]

Fresenius Kabi SA (Pty) Ltd

VAJL3 MAAA0007374 P O Box 4156 HALFWAY HOUSE 1685

Jeannine Terblanche (011) 545 0000 [email protected]

Lundbeck SA (Pty) Ltd VVS90 MAAA0031052 P O Box 2171 NORTHRIDING 2162

Julianne Howarth (011) 699-1600 (078) 800-3843

[email protected]

Litha Pharma (Pty) Ltd (Acino Pharma)

VGS73 MAAA0009244 P O Box 8356 MIDRAND 1685

Anand Reddy (011) 516-1700 (066) 304-6900

[email protected]


(PAGE 4)



E-mail

Macleods Pharmaceuticals SA (Pty) Ltd

V3PJ1 MAAA0007167 Office Block 1, Bassonia Estate Office Park (East) 1 Cussonia Drive Bassonia Rock Ext 12 ALBERTON 2061

Vanita Rajool (011) 628-1169 (083) 266-9223

[email protected]

Mylan (Pty) Ltd V3PS6 MAAA0081441 Postnet Suite X23 Private Bag X10010 EDENVALE 1610

Kumaraswamy Ekhambaram

(011) 451-1300 (071) 473-3900

[email protected]

Novartis SA (Pty) Ltd VBVW2 MAAA0006317 Magula Cresent West, Waterfall City Lukskei Vlei MIDRAND 2090

Masego Masipa (011) 347-6600 (082) 805-1262

[email protected]

Novo Nordisk (Pty) Ltd V2743 MAAA0013414 P O Box 783155 SANDTON 2146

Venkata Kalyan Papa Konduri

(011) 202-0500 (079) 694-1953

[email protected]

P & G South African Trading (Pty) Ltd

VJDY7 MAAA0913191 Private Bag X10062 SANDTON 2196

Deon Labuschagne (010) 001-9650 (082) 897-3611

[email protected]

Pfizer Laboratories (Pty) Ltd

V2189 MAAA0019202 85 Bute Lane SANDTON 2146

Themba Mnguni (011) 320-6091 (082) 307-9658

[email protected]

Pharmacare Limited V2205 MAAA0008452 P O Box 1587 GALLO MANOR 2052

Itumeleng Mathe (011) 239-6243 (083) 298-4366

[email protected]


(PAGE 5)



E-mail

Pharmaco Distribution (Pty) Ltd

VBVW1 MAAA0044115 P O Box 786522 SANDTON 2146

Jan van den Berg (011) 784-0077 (082) 572-7832

[email protected]

Pharma-Q (Pty) Ltd V1NK1 MAAA0016762 Private Bag X09 FLORIDA 1710

Anand Mehta (011) 247-1600 (083) 636-4444

[email protected]

Piramal Critical Care SA (Pty) Ltd

VFPD3 MAAA0655823 P O Box 1088 CRESTA 2188

Divya Ranchod (011) 678-1948 (082) 454-1781

[email protected]

Ranbaxy Pharmaceuticals (Pty) Ltd

V4728 MAAA0000384 P O Box 43486 INDUSTRIA 2042

Deepakh Sewnarain (012) 643-2000 (082) 893-8649

[email protected]

Safeline Pharmaceuticals (Pty) Ltd

VZL63 MAAA0002530 P O Box 7900 PALMCOURT 1709

Kay Naidu (011) 288-5360 (082) 459-2709

[email protected]

Sandoz SA (Pty) Ltd VVZ69 MAAA0011663 P O Box 12257 VORNA VALLEY 1686

Renee Moodley (011) 545-0424 (083) 704-1806

[email protected]

Sanofi-Aventis SA (Pty) Ltd

V2160 MAAA0009069 Private Bag X207 MIDRAND 1685

Jaidev Maharaj (011) 847-5264 (082) 943-3952

[email protected]

Specpharm (Pty) Ltd V3EQ1 MAAA0009737 P O Box 651 HALFWAY HOUSE 1685

Gregory Hill (011) 652-0465 (073) 676-0775

[email protected]

Unimed Healthcare (Pty) Ltd

V92D6 MAAA0444639 Private Bag X12 PRETORIA WEST 0117

Arshad Bera (011) 056- 6999 (083) 647-7860

[email protected]

HP06-2021SVP: SUPPLY AND DELIVERY OF SMALL VOLUME PARENTERALS AND INSULIN DEVICES TO THE DEPARTMENT OF HEALTH

CONTRACT CIRCULARVERSION 2

FOR THE PERIOD 01 MAY 2021 TO 30 APRIL 2024

Item No Item Specification *ADD Estimate Quantity Awarded

Split Supplier Name Central Supplier Database Number

Supplier CodeV-Number

Registered Product Name Delivered Price

Pack Size Offered: Unit Pack

Lead-Time (≤ 14 calendar

days)

MOQ Total Score

National Stock Number

UOM

1 Acetylcysteine 200mg/ml, injection, 10ml 213 295 213 295 100% Equity Pharmaceuticals (Pty) Ltd MAAA0007480 V1QZ3 Paradote R196.00 1 x 10 vials 14 1 x 10 vials 91.00 181915188 VI

2 Adenosine 3mg/ml, injection, 2ml 74 740 74 740 100% Sanofi-Aventis SA (Pty) Ltd MAAA0009069 V2160 ADENOCOR VIALS 6MG / 2ML 6 R156.21 1 x 1 14 6 91.00 180373081 VI

3 Adrenaline (Epinephrine) 0.15mg/0.3ml, auto-injection, 0.3ml

5 570 5 570 100% Mylan (Pty) Ltd MAAA0081441 V3PS6 EPIPEN JUNOR AUTO-INJECTOR R760.00 1 x 1 14 10 93.00 222000173 EA

4 Adrenaline (Epinephrine) 0.3mg/0.3ml, auto-injection, 0.3ml

2 336 2 336 100% Mylan (Pty) Ltd MAAA0081441 V3PS6 EPIPEN R749.00 1 x 1 14 10 93.00 222000174 EA

5 Adrenaline (Epinephrine) 1mg/ml, injection, 1ml

7 520 710 6 768 639 90% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 Pharma-Q Adrenaline Inj 1mg/1ml R4.00 1 x 10 14 500 96.00 180075485 AM

5 Adrenaline (Epinephrine) 1mg/ml, injection, 1ml

Product awarded:Adrenaline (Epinephrine) 1mg/ml, injection, 1mlRemaining shelf life: 4 - 10 months

1

752 071 10% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 ADRENALINE FRESENIUS 1 mg/1 ml (1:1000) R4.84 1 x 1 14 10 Amps 72.10 180075485 AM

6 Alfentanil 0.5mg/ml, injection, 2ml 119 310 119 310 100% Piramal Critical Care SA (Pty) Ltd MAAA0655823 VFPD3 Rapifen 2ml R49.83 5 x 2ml amps 14 5 x 2ml amps 90.00 180075489 AM

7 Alprostadil 0.5mg/ml, injection, 1ml

Product awarded:Alprostadil 0.5mg/ml, injection, 1ml1 pack of 5 injections

Price vs Pack size:1 x 1 injection = R2,744.601 x 5 injections = R13,723.09

6 250 6 250 100% Pfizer Laboratories (Pty) Ltd MAAA0019202 V2189 PROSTIN VR R2 744.60 1 x 5 14 5 91.00 180075498 AM

9 Aminophylline 25mg/ml, injection, 10ml 354 560 354 560 100% Adcock Ingram Critical Care (Pty) Ltd MAAA0010153 V4222 Sabax Aminophylline IV R3.57 1 x 10 vials 14 10 99.87 189700102 AM

10 Amiodarone 50mg/ml, injection, 3ml 223 660 223 660 100% Sanofi-Aventis SA (Pty) Ltd MAAA0009069 V2160 CORDARONE X IV 150MG/3ML 6 R61.09 1 x 1 14 6 91.00 180075509 AM

11 Atracurium 10mg/ml, injection, 2.5ml 81 270 81 270 100% Pharmacare Limited MAAA0008452 V2205 Tracrium Inj 5x2.5ml R78.66 5 x 2.5ml 14 5 95.00 180075518 AM

12 Atracurium 10mg/ml, injection, 5ml 58 400 58 400 100% Pharmacare Limited MAAA0008452 V2205 Tracrium Inj 5x5ml R158.41 5 x 5ml 14 5 95.00 180075520 AM

13 Atropine 0.5mg/ml, injection, 1ml 1 278 840 1 023 072 80% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 Pharma-Q Atropine Inj. 0,5mg/1ml R4.00 1 x 10 14 500 96.00 189707023 AM

13 Atropine 0.5mg/ml, injection, 1ml1

1 278 840 255 768 20% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 ATROPINE SULPHATE FRESENIUS 0.5 mg/1 ml R4.43 1 x 1 14 10 Amps 81.33 189707023 AM

14 Atropine 1mg injection, 1ml 2 353 110 1 882 488 80% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 Pharma-Q Atropine Inj. 1mg/1ml R4.20 1 x 10 14 400 96.00 189707024 AM

14 Atropine 1mg injection, 1ml 1 2 353 110 470 622 20% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 ATROPINE SULPHATE FRESENIUS 1.0 mg/1 ml R4.78 1 x 1 14 10 Amps 78.57 189707024 AM

15 Betamethasone 4mg/ml, injection, 1ml 1 199 860 1 199 860 100% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 Pharma-Q Betamethasone 4mg/1ml R4.75 1 x 10 14 400 96.00 180075545 AM

16 Biperiden 5mg, injection, 1ml 63 180 63 180 100% Pharmaco Distribution (Pty) Ltd MAAA0044115 VBVW1 AKINETON R45.17 1 x 5 14 5 90.00 180075548 AM

17 Bupivacaine 5mg, Adrenaline 5mcg/ml, injection, 20ml

292 780 292 780 100% Adcock Ingram Critical Care (Pty) Ltd MAAA0010153 V4222 MACAINE HCL 0,5% INJECTION WITH ADRENALINE

R31.05 1 x 10 vials 14 10 100.00 180075555 AM

18 Bupivacaine 5mg, Dextrose Anhydrous 72.7mg/ml, injection, 4ml

974 370 974 370 100% Adcock Ingram Critical Care (Pty) Ltd MAAA0010153 V4222 MACAINE HCL 0.5% SPINAL INJECTION WITH DEXTROSE

R4.60 1 x 10 14 10 100.00 180075556 AM

19 Bupivacaine 5mg/ml injection, spinal, 4ml 206 140 206 140 100% Adcock Ingram Critical Care (Pty) Ltd MAAA0010153 V4222 MACAINE HCL 0.5% SPINAL INJECTION R16.68 1 x 10 14 10 100.00 180075553 AM

Page 1 of 8










days)

MOQ Total Score


UOM

20 Bupivacaine 5mg/ml, injection, 10ml 971 660 971 660 100% Adcock Ingram Critical Care (Pty) Ltd MAAA0010153 V4222 MACAINE HCL 0.5% INJECTION R6.90 1 x 10 14 10 100.00 180075551 AM

21 Caffeine 20mg/ml, injection, 1ml 1 185 250 185 250 100% Safeline Pharmaceuticals (Pty) Ltd MAAA0002530 VZL63 CAYONA 20mg/ml R380.73 1 x 1 14 100 92.00 222001198 EA

22 Calcium gluconate 10% m/v, injection, 10ml 1 754 340 754 340 100% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 CALCIUM GLUGONATE FRESENIUS R12.65 1 x 1 14 10 Amps 91.00 180075565 AM

23 Cisatracurium 2mg/ml, injection, 2.5 ml 266 650 239 985 90% Accord Healthcare (Pty) Ltd MAAA0005335 V2MB8 Cistrax 5mg/2.5ml R25.30 1 x 5 14 20 91.00 181767288 AM

23 Cisatracurium 2mg/ml, injection, 2.5 ml 266 650 26 665 10% 181767288 AM

24 Cisatracurium 2mg/ml, injection, 5ml 237 390 166 173 70% Accord Healthcare (Pty) Ltd MAAA0005335 V2MB8 Cistrax 10mg/5ml R37.95 1 x 5 14 20 91.00 180308024 AM

24 Cisatracurium 2mg/ml, injection, 5ml 237 390 71 217 30% 180308024 AM

26 Clotiapine 10mg/ml, injection, 4ml 78 395 78 395 100% Pharmaco Distribution (Pty) Ltd MAAA0044115 VBVW1 ETOMINE R28.72 1 x 10 14 10 90.00 180075729 AM

29 Desmopressin 4mcg, injection, 1ml 9 660 9 660 100% Ferring (Pty) Ltd MAAA0005879 VXY92 DDAVP INJECTION 4MCG/ML 1ML R97.95 1 x 10 ampoules per

pack

14 5 x 10 ampoules pack (50

ampoules)

90.00 180075757 AM

30 Dexamethasone 4mg, injection, 1ml 5 270 300 4 743 270 90% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 Pharma-Q Dexamethasone Phosphate Inj. 4mg/1ml R5.40 1 x 10 14 400 96.00 180075759 AM

30 Dexamethasone 4mg, injection, 1ml 1 5 270 300 527 030 10% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 FRESENIUS DEXAMETHASONE 4 mg/1 ml R8.70 1 x 1 14 10 Amps 36.00 180075759 AM

31 Dexmedetomidine, 100 mcg/ml, Injection for infusion, 2ml

Product awarded:Dexmedetomidine, 100 mcg/ml, Injection for infusion, 2ml1 pack of 5 injections

Price vs Pack size:1 x 1 injection = R510.821 x 5 injections = R2,554.10

58 320 58 320 100% Pfizer Laboratories (Pty) Ltd MAAA0019202 V2189 PreceDEX R510.82 1 x 5 14 5 91.00 181937349 AM

32 Dextrose 50% m/v, injection, 20ml 1 1 293 980 1 293 980 100% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 DEXTROSE FRESENIUS 50 % (20 ml) INJECTION R19.81 1 x 1 14 10 Amps 91.00 180075794 AM

33 Dextrose 50% m/v, injection, 50ml 1 1 140 740 1 140 740 100% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 DEXTROSE-FRESENIUS 50% (50ml) R28.55 1 x 1 14 60 Bags 91.00 180352804 BG

34 Diazepam 5mg/ml, injection, 2ml 771 330 771 330 100% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 Pharma-Q Diazepam Inj. 10mg/2ml R4.00 1 x 10 14 400 96.00 180075798 AM

35 Diclofenac 25mg/ml, injection, 3ml 8 327 390 6 661 912 80% Unimed Healthcare (Pty) Ltd MAAA0444639 V92D6 Diclofenac Injection Unimed R1.52 1 x 50 14 750 100.00 180075799 AM

35 Diclofenac 25mg/ml, injection, 3ml 8 327 390 1 665 478 20% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 Dicon 75 inj R1.65 1 x 50 14 500 88.30 180075799 AM

36 Digoxin 0,25mg/ml, injection, 2ml 39 280 39 280 100% Pharmacare Limited MAAA0008452 V2205 Lanoxin 0.5mg Inj 5 x 2ml R21.39 5 x 2ml 14 5 95.00 180075803 AM

38 Dobutamine 12.5mg/ml, injection, 20ml 1 206 440 206 440 100% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 DOBUTAMINE FRESENIUS 250 mg/20 ml R75.44 1 x 1 14 5 Amps 91.00 189715235 VI

39 Dopamine 40mg/ml, injection, 5ml 106 755 106 755 100% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 Pharma-Q Dopamine Concentrate Inj. 200mg/5ml R7.80 1 x 10 14 250 96.00 180075879 AM

40 Enoxaparin 40mg, injection, 0.4ml 8 663 680 8 663 680 100% Sanofi-Aventis SA (Pty) Ltd MAAA0009069 V2160 CLEXANE PF SYRINGE 40mg 10 X 0.4ML R53.61 1 x 1 14 10 91.00 180077964 SG

41 Enoxaparin 60mg, injection, 0.6ml 901 800 901 800 100% Sanofi-Aventis SA (Pty) Ltd MAAA0009069 V2160 CLEXANE PF SYRINGE 60mg 10 X 0.6ML R67.49 1 x 1 14 10 91.00 222000901 SG

TO FOLLOW

TO FOLLOW

Page 2 of 8










days)

MOQ Total Score


UOM

42 Enoxaparin 80mg, injection, 0.8ml 2 019 230 2 019 230 100% Sanofi-Aventis SA (Pty) Ltd MAAA0009069 V2160 CLEXANE PF SYRINGE 80mg 10 X 0.8ML R81.50 1 x 1 14 10 91.00 180970533 EA

50 Etomidate 2mg/ml, injection, 10ml 145 080 145 080 100% Piramal Critical Care SA (Pty) Ltd MAAA0655823 VFPD3 Hypnomidate R36.74 5 x 10ml amps 14 5 x 10ml amps 90.00 180075956 AM

51 Fentanyl 0.05mg/ml, injection, 2ml 1 581 570 1 423 413 90% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 Pharma-Q Fentanyl Inj. 100ug/2ml R4.70 1 x 10 14 400 96.00 180075959 AM

51 Fentanyl 0.05mg/ml, injection, 2ml

Product awarded:Fentanyl 0.05mg/ml, injection, 2ml1 pack of 10 injections

Price vs Pack size:1 x 1 injection = R7.221 x 10 injections = R72.20

1 1 581 570 158 157 10% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 FENTANYL FRESENIUS 100 mcg/2 ml R7.22 1 x 10 14 10 Amps 42.74 180075959 AM

52 Fentanyl 0.05mg/ml, injection, 10ml 370 850 370 850 100% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 Pharma-Q Fentanyl Inj. 500ug/10ml R10.20 1 x 10 14 200 96.00 180075960 AM

54 Flupenthixol decanoate 20mg/ml, injection, 1ml

1 507 530 1 507 530 100% Lundbeck SA (Pty) Ltd MAAA0031052 VVS90 Fluanxol Depot 20 mg/ml R36.06 1 x 1 14 5 90.00 180017761 AM

55 Furosemide 10mg/ml, injection, 25ml 1 245 280 245 280 100% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 FRUSEMIDE FRESENIUS 250 mg/25 ml R23.92 1 x 1 14 10 Amps 91.00 180075988 AM

56 Furosemide 10mg/ml, injection, 2ml 7 085 900 7 085 900 100% Adcock Ingram Critical Care (Pty) Ltd MAAA0010153 V4222 ADCO FUROSEMIDE 20MG/2ML R2.97 1 x 10 vials 14 10 100.00 180075982 AM

57 Furosemide 10mg/ml, injection, 5ml 342 230 342 230 100% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 Pharma-Q Furosemide Inj. 50mg/5ml R5.55 1 x 10 14 300 96.00 180075985 AM

58 Glucagon 1mg, injection, 1ml 30 050 30 050 100% Novo Nordisk (Pty) Ltd MAAA0013414 V2743 GLUCAGEN HYPOKIT R394.98 1 x 1 14 1 92.00 180309135 VI

60 Glycopyrronium bromide 0.2mg/ml, injection, 2ml

622 200 622 200 100% Pharmacare Limited MAAA0008452 V2205 Robinul Inj 2ml R12.84 10 x 2ml 14 10 95.00 180075998 AM

65 Hydrocortisone 100mg/2ml, injection, 2ml 4 166 740 3 750 066 90% Macleods Pharmaceuticals SA (Pty) Ltd MAAA0007167 V3PJ1 Macleods Hydrocortisone Injection R17.37 1 x 2ml 14 100 95.00 180018040 VI

65 Hydrocortisone 100mg/2ml, injection, 2ml

Product awarded:Hydrocortisone 100mg/2ml, injection, 2ml1 pack of 5 injections


4 166 740 416 674 10% Pfizer Laboratories (Pty) Ltd MAAA0019202 V2189 SOLU-CORTEF 100mg R39.34 1 x 5 14 5 -22.83 180018040 VI

66 Hyoscine Butylbromide 20mg, injection, 1ml 2 338 110 2 338 110 100% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 Pharma-Q Hyoscine Butylbromide Inj. 20mg/1ml R5.30 1 x 10 14 300 96.00 180076081 AM

67 Insulin analogue, Human, Long-acting, 100 u/ml, disposable pen, 3ml

33 860 33 860 100% Sanofi-Aventis SA (Pty) Ltd MAAA0009069 V2160 OPTISULIN SOLOSTAR 3ML 5 R51.06 1 x 1 14 5 91.00 222000179 EA

68 Insulin analogue, Human, Ultrafast-acting 100 u/ml, disposable pen, 3ml

229 559 229 559 100% Sanofi-Aventis SA (Pty) Ltd MAAA0009069 V2160 APIDRA SOLOSTAR 100IU/ML 3 ML 5 R72.68 1 x 1 14 5 91.00 222000181 EA

69 Insulin analogue, Human, Ultrafast-acting 100 u/ml, vial, 10ml

1 540 1 540 100% Sanofi-Aventis SA (Pty) Ltd MAAA0009069 V2160 APIDRA VIALS 10ML 1 R244.95 1 x 1 14 10 91.00 222000182 VI

70 Insulin, Biosynthetic, Human, Isophane, 100 u/ml, disposable pen, 3ml

2 832 200 2 832 200 100% Novo Nordisk (Pty) Ltd MAAA0013414 V2743 PROTAPHANE HM R32.06 1 x 5 14 10 92.00 180309126 SG

71 Insulin, Biosynthetic, Human, Isophane, 100 u/ml, vial, 10ml

903 640 903 640 100% Novo Nordisk (Pty) Ltd MAAA0013414 V2743 PROTAPHANE HM R34.14 1 x 1 14 10 92.00 189710587 VI

Page 3 of 8










days)

MOQ Total Score


UOM

72 Insulin, Biosynthetic, Human, Biphasic, 100 u/ml, soluble 30% and Isophane 70%, disposable pen, 3ml

13 676 740 13 676 740 100% Novo Nordisk (Pty) Ltd MAAA0013414 V2743 ACTRAPHANE HM R30.37 1 x 5 14 10 92.00 180309129 SG

74 Insulin, Biosynthetic, Human, Biphasic, 100 u/ml, soluble 30% and Isophane 70%, vial, 10ml

4 520 360 4 520 360 100% Novo Nordisk (Pty) Ltd MAAA0013414 V2743 ACTRAPHANE HM R34.14 1 x 1 14 10 92.00 189711634 VI

75 Insulin, Biosynthetic, Human, Soluble, 100 u/ml, disposable pen, 3ml

1 886 440 1 886 440 100% Novo Nordisk (Pty) Ltd MAAA0013414 V2743 ACTRAPID HM R32.06 1 x 5 14 10 92.00 180309128 SG

76 Insulin, Biosynthetic, Human, Soluble, 100 u/ml, vial, 10ml

387 840 387 840 100% Novo Nordisk (Pty) Ltd MAAA0013414 V2743 ACTRAPID HM R34.14 1 x 1 14 10 92.00 189710585 VI

77 Iron dextran containing elemental iron 50mg/ml, injection, 10ml

16 500 16 500 100% Litha Pharma (Pty) Ltd (Acino Pharma) MAAA0009244 VGS73 COSMOFER R310.13 1 x 2 14 1 x 2 100.00 181871852 AM

78 Iron dextran containing elemental iron 50mg/ml, injection, 2ml

211 350 211 350 100% Litha Pharma (Pty) Ltd (Acino Pharma) MAAA0009244 VGS73 COSMOFER R62.03 1 x 5 14 1 x 5 100.00 181891028 AM

79 Iron sucrose containing elemental iron 20mg/ml, injection, 5ml

271 550 271 550 100% Actor Pharma (Pty) Ltd MAAA0183044 V2G28 Rautevene R48.53 5 x 5ml ampules

14 50 90.00 180185678 AM

80 Isulin analogue, Human, Ultrafast-acting 100 u/ml, penfill cartridge for use in pens, 3ml(PENS TO BE PROVIDED FREE OF CHARGE TO PATIENTS)

7 725 7 725 100% Sanofi-Aventis SA (Pty) Ltd MAAA0009069 V2160 APIDRA 300IU CART 5 R69.46 1 x 1 14 5 91.00 222000180 EA

81 Ketamine 10mg/ml, injection, 20ml 1 96 930 96 930 100% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 KETAMINE FRESENIUS 10 mg/1 ml R37.03 1 x 1 14 10 Vials 91.00 189710933 VI



85 Lidocaine 1% m/v, injection, not for iv use, 20ml

1 821 100 1 821 100 100% B Braun Medical (Pty) Ltd MAAA0040832 VYL89 Lignocaine-HCL B.Braun 1% 20ml (Product Code: 3659091)

R8.38 1 x 1 14 20 96.00 180076306 VI

86 Lidocaine 10% m/v, iv injection, 5ml 1 39 220 39 220 100% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 LIGNOCAINE HCI FRESENIUS 10% (AMPOULES) R12.07 1 x 1 14 10 Amps 91.00 180076360 AM

87 Lidocaine 2% m/v injection, not for iv use, 20ml

1 191 930 1 191 930 100% B Braun Medical (Pty) Ltd MAAA0040832 VYL89 Lignocaine-HCL B.Braun 2% 20ml (Product Code: 3659089)

R8.67 1 x 1 14 20 96.00 189703157 VI

88 Lidocaine 2% m/v, Adrenaline 12.5mcg (1:80 000), dental cartridge, 1.8ml

18 119 370 18 119 370 100% Adcock Ingram Healthcare (Pty) Ltd MAAA0036413 V2272 Xylotox E80-A 6.79 100 x 1.8ml box 14 1 x 100 x 1.8ml 100.00 180076312 CA

89 Lidocaine 2% m/v, dental cartridge, 1.8ml 2 814 860 2 814 860 100% Adcock Ingram Healthcare (Pty) Ltd MAAA0036413 V2272 Xylotox S.E. Plain 6.79 100 x 1.8ml box 14 1 x 100 x 1.8ml 99.93 180076343 CA

90 Lidocaine 2% m/v, iv injection, 5ml 1 964 420 1 964 420 100% B Braun Medical (Pty) Ltd MAAA0040832 VYL89 Lignocaine-HCL B. Braun 2% 5ml (Product Code: 3659970)

R2.89 1 x 1 14 20 96.00 180076308 AM

92 Magnesium sulfate 50%, injection, 2ml 5 111 040 5 111 040 100% Adcock Ingram Critical Care (Pty) Ltd MAAA0010153 V4222 SABAX MAGNESIUM SULPHATE 50% R3.45 1 x 10 vials 14 10 100.00 189710942 AM

93 Mannitol 25% m/v, injection, 50ml

Product awarded:Mannitol 25% m/v, injection, 50ml1 pack of 60 bagsRemaining shelf life: 4 - 10 months

Price vs Pack size:1 x 1 bag = R49.511 x 60 bags = R2,970.60

1 19 320 19 320 100% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 MANNITOL FRESENIUS 25 % INJECTION R49.51 1 x 1 14 60 Bags 91.00 189704505 AM

96 Methylprednisolone 500mg, (as sodium succinate) injection, 8ml

100 830 100 830 100% Pfizer Laboratories (Pty) Ltd MAAA0019202 V2189 SOLU-MEDROL 500mg R159.91 1 x 1 14 1 91.00 189710955 VI

97 Methylprednisolone acetate 40mg/ml, injection, 2ml

257 150 257 150 100% Pfizer Laboratories (Pty) Ltd MAAA0019202 V2189 DEPO-MEDROL 40 mg R34.88 1 x 1 14 1 91.00 189710776 VI

Page 4 of 8










days)

MOQ Total Score


UOM

98 Methylprednisolone acetate 40mg/ml, injection, 5ml

18 412 18 412 100% Pfizer Laboratories (Pty) Ltd MAAA0019202 V2189 DEPO-MEDROL 40 mg R97.18 1 x 1 14 1 91.00 189710775 VI

99 Metoclopramide 5mg/ml, injection, 2ml 7 601 990 760 199 10% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 Pharma-Q Metoclopramide Inj 10mg/2ml R3.45 1 x 10 14 400 44.86 180076396 AM

99 Metoclopramide 5mg/ml, injection, 2ml 7 601 990 6 841 791 90% 180076396 AM

100 Midazolam 1mg/ml, injection, 5ml 595 200 357 120 60% Adcock Ingram Critical Care (Pty) Ltd MAAA0010153 V4222 ADCO MIDAZOLAM INJECTION 5MG/5ML R6.21 1 x 10 14 10 92.80 180076401 AM

100 Midazolam 1mg/ml, injection, 5ml 595 200 238 080 40% Accord Healthcare (Pty) Ltd MAAA0005335 V2MB8 Accord Midazolam 5 mg/5 ml R5.75 1 x 10 14 20 91.00 180076401 AM

101 Midazolam 5mg/ml, injection, 10ml 127 300 127 300 100% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 Pharma-Q Midazolam Inj. 50mg/10ml R19.25 1 x 10 14 100 96.00 180018352 AM

102 Midazolam 5mg/ml, injection, 3ml 948 930 569 358 60% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 Pharma-Q Midazolam Inj. 15mg/3ml R7.50 1 x 5 14 300 96.00 180076404 AM

102 Midazolam 5mg/ml, injection, 3ml

Product awarded:Midazolam 5mg/ml, injection, 3ml1 pack of 10 injections


948 930 379 572 40% Adcock Ingram Critical Care (Pty) Ltd MAAA0010153 V4222 ADCO MIDAZOLAM INJECTION 15MG/3ML R8.17 1 x 10 14 10 91.96 180076404 AM

103 Morphine 10mg/ml, injection, 1ml 3 307 110 2 976 399 90% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 Pharma-Q Morphine Inj. 10mg/1ml R3.90 1 x 10 14 300 96.00 189703413 AM

103 Morphine 10mg/ml, injection, 1ml 1 3 307 110 330 711 10% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 MORPHINE SULPHATE FRESENIUS PF 10 mg/1 ml

R5.24 1 x 1 14 10 Amps 60.08 189703413 AM

104 Morphine 15mg/ml, injection, 1ml 1 772 750 1 595 475 90% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 Pharma-Q Morphine Inj. 15mg/1ml R4.10 1 x 10 14 300 96.00 189700425 AM

104 Morphine 15mg/ml, injection, 1ml 1 1 772 750 177 275 10% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 MORPHINE SULPHATE FRESENIUS PF 15 mg/1 ml

R5.35 1 x 1 14 10 Amps 63.56 189700425 AM

105 Naloxone 0.02mg/ml, injection, 2ml 1 96 540 96 540 100% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 NALOXONE HCI NEONATAL FRESENIUS 0.02 mg/1 ml

R9.05 1 x 1 14 10 Amps 91.00 189708068 AM

106 Naloxone 0.4mg/ml, injection, 1ml 1 504 980 504 980 100% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 NALOXONE HCI FRESENIUS 0.4 mg/1 ml R7.61 1 x 1 14 10 Amps 91.00 189705061 AM

109 Needle, Insulin, 31G x 5mm, sterile, suitable for use with all prefilled insulin injection devices, 100

82 770 82 770 100% Unimed Healthcare (Pty) Ltd MAAA0444639 V92D6 INSUPEN 31g X 5mm R60.02 1 x 100 14 36 95.61 181915212 BX

110 Needle, Insulin, 31G x 8mm, sterile, suitable for use with all prefilled insulin injection devices, 100

377 460 377 460 100% Unimed Healthcare (Pty) Ltd MAAA0444639 V92D6 INSUPEN 31g X 8mm R56.48 1 x 100 14 36 99.10 181915214 BX

112 Neostigmine 2.5mg, injection, 1ml 481 450 481 450 100% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 Pharma-Q Neostigmine Methyl Sulphate Inj. 2.5mg/1ml

R6.16 1 x 10 14 200 96.00 180089506 AM

113 Octreotide 0.05mg, injection, 1ml 14 020 14 020 100% Novartis SA (Pty) Ltd MAAA0006317 VBVW2 Sandostatin 0.05mg R 104.36 1 x 5 14 1 91.00 180076442 AM

114 Octreotide 0.1mg, injection, 1ml 119 395 119 395 100% Novartis SA (Pty) Ltd MAAA0006317 VBVW2 Sandostatin 0.1mg R 199.10 1 x 5 14 1 91.00 180076445 AM

116 Oxytocin 10 iu, injection, 1ml 6 406 260 3 203 130 50% Specpharm (Pty) Ltd MAAA0009737 V3EQ1 Spec Oxytocin 10iu R15.25 1 x 10 14 1 pack of 10's 99.00 180076472 AM

117 Oxytocin 5 iu, injection, 1ml 2 063 960 1 031 980 50% Specpharm (Pty) Ltd MAAA0009737 V3EQ1 Spec Oxytocin 5iu R14.77 1 x 10 14 1 pack of 10's 99.00 180076470 AM

118 Oxytocin 5iu, Ergometrine 0.5mg, injection, 1ml

538 290 538 290 100% Adcock Ingram Critical Care (Pty) Ltd MAAA0010153 V4222 SYNTOMETRINE R27.85 1 x 5 14 5 100.00 180076474 AM

TO FOLLOW

Page 5 of 8










days)

MOQ Total Score


UOM

119 Pantoprazole 40mg, injection, 10ml 1 042 800 1 042 800 100% Ranbaxy Pharmaceuticals (Pty) Ltd MAAA0000384 V4728 PANTOCID 40MG INJECTION 10ML R22.94 1 x 1 14 10 95.00 181753528 VI

120 Paracetamol 10mg/ml, injection for IV infusion, 100ml

1 585 240 1 585 240 100% Biotech Laboratories (Pty) Ltd MAAA0029826 VUV35 PARACETAMOL BIOTECH IV R11.74 1 x 100ml 14 10 96.00 181818827 VI

122 Pethidine 25mg/ml, injection, 1ml 354 260 354 260 100% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 Pharma-Q Pethidine Inj. 25mg/1ml R4.60 1 x 10 14 400 96.00 189703124 AM

123 Pethidine 50mg/ml, injection, 1ml 1 815 320 1 452 256 80% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 Pharma-Q Pethidine Inj. 50mg/1ml R4.20 1 x 10 14 400 96.00 180076519 AM

123 Pethidine 50mg/ml, injection, 1ml 1 1 815 320 363 064 20% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 PETHIDINE HCI FRESENIUS PF 50 mg/1 ml R4.67 1 x 1 14 10 Amps 80.93 180076519 AM

124 Pethidine 50mg/ml, injection, 2ml 2 769 710 2 492 739 90% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 Pharma-Q Pethidine Inj. 100mg/2ml R4.90 1 x 10 14 400 96.00 180076540 AM

124 Pethidine 50mg/ml, injection, 2ml 1 2 769 710 276 971 10% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 PETHIDINE HCI FRESENIUS PF 100 mg/2 ml R6.21 1 x 1 14 10 Amps 66.94 180076540 AM

125 Phenylephrine 10mg, injection, 1ml

Product awarded:Phenylephrine 10mg, injection, 1ml1 pack of 5 injections


637 460 637 460 100% Abbott Laboratories South Africa (Pty) Ltd MAAA0030395 V2150 Phenylephrine 10mg, injection, 1ml R67.02 1 x 5 14 1 x 5 94.00 180076556 AM

126 Phenytoin 50mg/ml, injection, 5ml 1 278 200 1 278 200 100% Ascendis Pharma (Pty) Ltd MAAA0043637 V0DM6 Phlexy 250 mg/5ml R42.48 1 x 5ml vial 14 10 vials 100.00 189708084 VI

127 Phospholipids, Total (Beractant), 100mg/4ml, 1 Vial

35 215 35 215 100% AbbVie (Pty) Ltd MAAA0076921 V3PG3 Survanta R1 631.44 1 x 4ml 14 10 91.00 181772157 VI

128 Phospholipids, Total (Beractant), 200mg/8ml, 1 Vial

17 274 17 274 100% AbbVie (Pty) Ltd MAAA0076921 V3PG3 Survanta R3 262.39 1 x 8ml 14 10 91.00 189753628 VI

129 Potassium Chloride 15%, m/v injection, 10ml

1 2 470 180 2 470 180 100% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 POTASSIUM CHLORIDE FRESENIUS 15 % (Flexivial)

R2.13 1 x 1 14 20 Flexivials 91.00 189710612 AM

130 Potassium Phosphate Monobasic, Anhydrous, Potassium Phosphate Dibasic Anhydrous, 1.09g/1.05g, injection, 10ml

131 090 131 090 100% Adcock Ingram Critical Care (Pty) Ltd MAAA0010153 V4222 SABAX POTASSIUM PHOSPHATE SOLUTION FOR INJECTION AFTER DILUTION

R60.38 1 x 10 14 10 100.00 180076573 AM

131 Promethazine 25mg/ml, injection, 1ml 1 691 430 691 430 100% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 PROMETHAZINE HCI FRESENIUS 25 mg R7.70 1 x 1 14 10 Amps 91.00 189703419 AM

132 Promethazine 25mg/ml, injection, 2ml 1 319 811 319 811 100% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 PROMETHAZINE HCI FRESENIUS 50 mg R8.22 1 x 1 14 10 Amps 91.00 189703420 AM

133 Propofol 10mg/ml, injection, 20ml 1 446 630 1 446 630 100% Biotech Laboratories (Pty) Ltd MAAA0029826 VUV35 MILSIA 1 % 20 ml R12.69 5 x 20ml 14 10 96.00 180076590 AM

134 Propofol 10mg/ml, injection, 50ml 195 590 195 590 100% Biotech Laboratories (Pty) Ltd MAAA0029826 VUV35 MILSIA 1 % 50 ml R37.54 1 x 50 ml 14 10 96.00 189763039 VI

136 Quinine 300mg, injection, 1ml 1 46 610 46 610 100% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 QUININE DIHYDROCHLORIDE FRESENIUS 300 mg/1 ml

R25.25 1 x 1 14 10 Vials 91.00 189706315 AM

137 Ranitidine 25mg/ml, injection, 2ml 822 410 822 410 100% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 CPL Alliance Ranitidine Inj. 50mg/2ml R2.95 1 x 10 14 500 96.00 180076594 AM

138 Remifentanil 2mg, injection, 5ml 47 070 47 070 100% Pharmacare Limited MAAA0008452 V2205 Fortiva 2 Inj 5x5ml R174.80 5 x 5ml 14 5 95.00 181757213 VI

139 Rocuronium 50mg, injection, 5ml 1 777 100 777 100 100% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 ROCURONIUM FRESENIUS 10 mg/ml (50 mg/5 ml)

R33.93 1 x 1 14 10 Vials 91.00 180960252 VI

Page 6 of 8










days)

MOQ Total Score


UOM

141 Sodium bicarbonate 4% m/v, injection, 50ml

Product awarded:Sodium bicarbonate 4% m/v, injection, 50ml1 pack of 60 bagsRemaining shelf life: 4 - 10 months

Price vs Pack size:1 x 1 bag = R58.151 x 60 bags = R3489.00

1 109 550 109 550 100% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 SODIUM BICARBONATE FRESENIUS 4 % INJECTION

R57.77 1 x 1 14 60 Bags 91.00 180358064 BG

142 Sodium bicarbonate 8.5% m/v, injection, 50ml

Product awarded:Sodium bicarbonate 8.5% m/v, injection, 50ml1 pack of 60 bagsRemaining shelf life: 4 - 10 months

Price vs Pack size:1 x 1 bag = R73.821 x 60 bags = R4429.20

1 578 010 578 010 100% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 SODIUM BICARBONATE FRESENIUS 8.5 % INJECTION

R73.33 1 x 1 14 60 Bags 91.00 180358068 BG

143 Sodium chloride 0.9% m/v, injection, 10ml 12 400 540 11 160 486 90% B Braun Medical (Pty) Ltd MAAA0040832 VYL89 0.9% Sodium Chloride Injection B. Braun (10ml) (Product Code: 3659990)

R1.48 1 x 1 14 100 96.00 189700088 AM

143 Sodium chloride 0.9% m/v, injection, 10ml 12 400 540 1 240 054 10% Adcock Ingram Critical Care (Pty) Ltd MAAA0010153 V4222 SODIUM CHLORIDE 0.9% ADCO R2.30 1 x 100 14 100 50.14 189700088 AM

144 Somatropin 15iu, powder for injection, cartridge + diluent

23 720 23 720 100% Novo Nordisk (Pty) Ltd MAAA0013414 V2743 NORDITROPIN NORDILET 5 MG R536.07 1 x 1 14 1 92.00 181808985 EA

145 Somatropin 30iu, powder for injection, cartridge + diluent

24 895 24 895 100% Sandoz SA (Pty) Ltd MAAA0011663 VVZ69 Omnitrope 10mg R1 016.00 1 x 1 14 100 91.00 181799365 EA

147 Streptokinase 1.5MU injection 10 155 10 155 100% Actor Pharma (Pty) Ltd MAAA0183044 V2G28 Fibreaker R4 640.80 1 x 1 14 5 90.00 189711674 VI

148 Suxamethonium 50mg/ml, injection, 2ml

Product awarded:Suxamethonium 50mg/ml, injection, 2mlRemaining shelf life: 4 - 10 months

1 635 010 635 010 100% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 SUXAMETHONIUM CHLORIDE-FRESENIUS 100 mg/2 ml

R12.71 1 x 1 14 10 x Amps 91.00 180076785 AM

152 Tranexamic Acid 100mg/ml, injection, 5ml

Product awarded:Tranexamic Acid 100mg/ml, injection, 5ml1 pack of 5 injections


1 734 980 1 734 980 100% Pfizer Laboratories (Pty) Ltd MAAA0019202 V2189 Cyklokapron IV 500 R37.60 1 x 5 14 5 91.00 180076981 AM

153 Vecuronium 4mg, injection, 2ml 53 840 53 840 100% Ranbaxy Pharmaceuticals (Pty) Ltd MAAA0000384 V4728 MUSCURON R45.94 1 x 1 14 5 95.00 222000188 EA

154 Verapamil HCl 2.5mg/ml, injection, 2ml 17 910 17 910 100% Pharma-Q (Pty) Ltd MAAA0016762 V1NK1 Pharma-Q Verapmil Inj. 5mg/2ml R7.20 1 x 10 14 100 96.00 180076998 AM

156 Vitamin B1 (Thiamine) 100mg/ml, injection, 10ml

412 200 412 200 100% Litha Pharma (Pty) Ltd (Acino Pharma) MAAA0009244 VGS73 LITHA THIAMINE INJECTION R37.56 1 x 10 14 1 x 10 100.00 189700006 VI

157 Vitamin B12 (Cyanocobalamin) 1000mcg, injection, 1ml

487 350 487 350 100% P & G South African Trading (Pty) Ltd MAAA0913191 VJDY7 Neurobion Ampoules R48.84 3 x 3ml 14 30 91.00 189715773 AM

Page 7 of 8










days)

MOQ Total Score


UOM

158 Vitamin K1 (Phytomenadione) 10mg/1ml, injection

773 990 773 990 100% Pharmaco Distribution (Pty) Ltd MAAA0044115 VBVW1 KONAKION R22.35 1 x 10 14 10 90.00 180146851 AM

159 Vitamin K1 (Phytomenadione) 2mg/0.2ml, injection

3 500 390 3 500 390 100% Pharmaco Distribution (Pty) Ltd MAAA0044115 VBVW1 KONAKION R13.04 1 x 5 14 5 90.00 180953330 AM

160 Water for injection BP, injection, 10ml 37 241 680 37 241 680 100% B Braun Medical (Pty) Ltd MAAA0040832 VYL89 Water for Injections B. Braun 10ml (Product Code: 3659980)

R1.27 1 x 1 14 100 96.00 189710871 AM

161 Water for injection BP, injection, 20ml 1 4 112 500 4 112 500 100% Fresenius Kabi SA (Pty) Ltd MAAA0007374 VAJL3 WATER FOR INJECTIONS FRESENIUS "FLEXIVIAL" 20 ml

R2.67 1 x 1 14 20 Flexivials 91.00 189710862 AM

162 Zuclopenthixol acetate 50mg, injection, 1ml 228 680 228 680 100% Lundbeck SA (Pty) Ltd MAAA0031052 VVS90 Clopixol Acuphase 50 mg/ml R94.90 1 x 1 14 5 90.00 189753243 AM

163 Zuclopenthixol decanoate 200mg/ml, injection, 1ml

2 142 750 2 142 750 100% Lundbeck SA (Pty) Ltd MAAA0031052 VVS90 Clopixol Depot 200mg/ml R49.82 1 x 1 14 5 90.00 180057631 AM

* ADDENDUM 1

AM Ampoule

BG Bag

BX Box

CA Cartridge

EA Each

SG Syringe

VI Vial

LEGEND UNIT OF MEASUE (UOM)

Page 8 of 8

S

PLEAS

SPE

SUPPLY AN

DEVIC

SE NOTE:

ECIAL REQ

ND DELIVE

CES TO TH

B

C

AN ERRA

NO

QUIREMEN

H

ERY OF SM

HE DEPAR

01 MAY 2

BID VALID

CLOSING D

24 JU

TUM WILL

TO 28

O BRIEFING

TS AND C

HP06-2021

MALL VOLU

RTMENT O

2021 TO 30

DITY PERIO

DATE AND

ULY 2020 A

L BE PUBL

8 SEPTEMB

G SESSION

ONDITION

SVP

UME PARE

F HEALTH

0 APRIL 20

OD: 120 DA

D TIME OF

AT 11H00

ISHED TO

BER 2020

N WILL BE

NS OF CON

ENTERALS

H FOR THE

024

AYS

BID:

AMEND T

HELD.

NTRACT

S AND INS

PERIOD

THE CLOSI

ULIN

ING DATE

TABLE1. LEGIS10. LATE11. COUN12. FRON13. SUPP14. COM15. CONT16. CONT17. PART18. REGI19. POST2. BID IN20. AWA21 NEGO22. NON-23. PRIC23.1 ELIG23.2 PRIC23.3 APP23.4 ROU23.5 EXC23.6 PRIC24. QUAL25. DELIV26. SUPP27. PACK28 SHEL29. CEDI3. EVALU3.1 PHAS3.1.1 LEG3.1.2 RES3.1.3 BID3.1.4 AUT3.1.5 TAX30. THIR4. PHASE4.2 COM5. PHASE6. PREFE7. VALUE8. SUBM9. COMPABBREVBID DOCSECTIONSECTIONSECTION

S

OF CONTENSLATIVE AND E BIDS ............NTER CONDITNTING ............PLIER DUE DILMUNICATION TACT DETAILSTRACT PERIOTICIPATING AUISTRATION ONT AWARD PAR

NFORMATION SARD CONDITIOOTIATIONS .....-COMMITMENT

CE REVIEW .....GIBILITY RELACE ADJUSTME

PLICATION FOUTINE PRICE ACEPTIONAL PRCE ADJUSTMELITY ..............VERY AND QUPLIER PERFORKAGING, LABE

LF LIFE ...........ING, MERGERSUATION CRITESE II: MANDATGISLATIVE RESPONSIVE BID

D RESPONSE DTHORISATIONX COMPLIANC

RD PARTIES ...E III: PRODUCTPLIANCE WITHE IV: PREFEREERENCE FOR E ADDED TAX

MISSION OF BIDPLETION OF DOVIATIONS .......CUMENT CHECN A ................N B ................N C ................

Special Requ

NTS REGULATORY......................

TIONS ...................................

LIGENCE ..............................S ....................

OD ...................UTORITIES ANN DATABASESRTICIPATION ..SESSION ........NS .......................................T ..........................................

ATING TO RATENTS RELATINR CONTRACT

ADJUSTMENTSRICE ADJUSTMENTS BASED O......................

UANTITIES ......RMANCE MANELLING AND B......................S, TAKE OVERERIA ...............TORY REQUIREEQUIREMENTSDS ..................DOCUMENT ....N DECLARATIOCE STATUS ...........................T TECHNICAL H SPECIFICATENCE POINT SLOCALLY PRO......................DS ..................OCUMENTS AN......................

CK LIST ............................................................................

uirements an

Y FRAMEWOR.................................................................................................................................................................

ND OTHER HEAS OF PARTICIP..........................................................................................................................................

TE OF EXCHANNG TO FOREIGUAL PRICE ADS ....................MENTS ............ON A SYSTEM..............................................AGEMENT......

BARCODES ............................RS AND CHANG.......................EMENTS .........

S TO THIS BID ...............................................ON ................................................................ COMPLIANCE

TIONS .............SYSTEM ..........ODUCED PROD..............................................ND BID SUBMI...................................................................................................................

nd Conditions

K .............................................................................................................................................................................ALTH ESTABLPATING AUTHO....................................................................................................................................

NGE ADJUSTMGN EXCHANGEDJUSTMENTS ............................................ATIC REVIEW ..............................................................................................................GES IN SUPPL................................................................................................................................................................................E ................................................................DUCTS .......................................................ISSION .........................................................................................................................

s of Contract

......................

......................

......................

......................

......................

......................

......................

......................IHSMENT .......

ORITIES ..............................................................................................................................................

MENTS ............E RISK ..................................................................................................................................................................................................................

LIER DETAILS .........................................................................................................................................................................................................................................................................................................................................................................................................................................................

: HP06-2021

.......................

.......................

.......................

.......................

.......................

.......................

.......................

.......................

.......................

.......................

.......................

.......................

.......................

.......................

.......................

.......................

.......................

.......................

.......................

.......................

.......................

.......................

.......................

.......................

.......................

.......................

.......................

.......................

.......................

.......................

.......................

.......................

.......................

.......................

.......................

.......................

.......................

.......................

.......................

.......................

.......................

.......................

.......................

.......................

.......................

.......................

.......................

.......................

SVP

Page 2 o

......................

......................

......................

......................

......................

......................

......................

......................

......................

......................

......................

......................

......................

......................

......................

......................

......................

......................

......................

......................

......................

......................

......................

......................

......................

......................

......................

......................

......................

......................

......................

......................

......................

......................

......................

......................

......................

......................

......................

......................

......................

......................

......................

......................

......................

......................

......................

......................

of 38

.................. 7

................ 18

................ 19

................ 19

................ 19

................ 19

................ 20

................ 21

................ 21

................ 21

................ 22

.................. 7

................ 22

................ 25

................ 25

................ 25

................ 26

................ 26

................ 27

................ 28

................ 28

................ 29

................ 29

................ 30

................ 31

................ 35

................ 37

................ 37

.................. 7

.................. 8

.................. 8

.................. 9

.................. 9

.................. 9

................ 10

................ 38

................ 11

................ 13

................ 13

................ 14

................ 15

................ 15

................ 17

.................. 3

.................. 4

.................. 7

................ 21

................ 31

ABBRE

API

BAC

B-BBEE

CPA

CSD

EAN

EME

GMP

MCC

MHPL

MPC

NDoH

PPPFA

QSE

RoE

SAHPRA

SARS

SBD

VAT

S

EVIATIONS

: Ac

: Bi

: Br

: Co

: Ce

: Eu

: Ex

: Go

: M

: M

: M

: Na

: Pre

: Qu

: Ra

A : So

: So

: St

: Va

Special Requ

ctive Pharmac

d Adjudication

road-Based Bl

ontract Price A

entral Supplier

uropean Article

xempted Micro

ood Manufactu

edicines Cont

aster Health P

aster Procurem

ational Depart

eferential Proc

ualifying Smal

ate of Exchang

outh African H

outh African Re

tandard Biddin

alue- Added T

uirements an

ceutical Ingred

n Committee

lack Economic

Adjustment

r Database

e Numbering

o Enterprise

uring Practice

rol Council

Products List

ment Catalogu

tment of Health

curement Polic

ll Enterprise

ge

Health Products

evenue Servic

ng Document

Tax

nd Conditions

ient

c Empowerme

ue

h

cy Framework

s Regulatory A

ce

s of Contract

ent

k Act

Authority

: HP06-2021SVP

Page 3 oof 38

BID DO

All bid d

below an

Submiss

All bid d

Bidders

evaluatio

CompilaSequen

1

2

3

4

5

6

7

8

9

10

11

12

S

OCUMENT CH

documents list

nd the annexu

sion of bid doc

documents m

not complying

on

ation nce

AdmCod

CL

BSR

BFI

PBD4

SBD5

TCP

CSD

SBD

PBD

SBD

SBD

BBBE

Special Requ

HECK LIST

ted below mus

ure attached.

cuments is com

must be signed

g to any of the

min de

Docum

L Coverin

RA Bid Sign

I Bid/File

4.1 PBD 4.1

5.1 SBD 1:

P Tax Cle

D CSD Relatest ansumma

D4 SBD 4:

D9 PBD9: Dgender

D5 SBD5: TProgram

D6 SBD 6(1BBEE)

EE Valid B-originapoints

uirements an

st be sorted, f

mpulsory, unle

d.

e requirements

ent Name

ng Letter

nature. Resolu

Index

1: Contact Det

Invitation to b

earance Pin Iss

egistration repnd complete reary report will

Declaration of

Directors: Cateand disability

The National Imme

1): Preference

-BBEE certifical) or Sworn Af

nd Conditions

filed and subm

ess it's not app

s may deeme

ution/Authority

tails of Bidder

id

sued

port - A certifiedeport. Note: l not be accep

f interest

egorisation by

ndustrial Parti

e Points Claim

ate(certified cffidavit to claim

s of Contract

mitted in the e

plicable and ind

d to be non-re

y to sign bid

d copy of CSD pted.

y race,

cipation

ed (B-

copy of the m preference

: HP06-2021

exact compila

dicated as suc

esponsive and

N/A Yes

SVP

Page 4 o

ation sequence

ch in the "N/A"

d will not be c

No

of 38

eas indicated

" column.

onsidered for

Remark

CompilaSequen

13

14

15

16

17

18

19

20

21

22

23

24

S

ation nce

AdmCod

SBD

SBD

PBD

PBD1

PBD1

PBD

PBD

CIPC

NC

LICM

LICM

MRC

Special Requ

min de

Docum

D8 SBD 8:

D9 SBD 9: Determi

D1 PBD1: ANote: Nauthorismay inv

1.1 PBD 1.1third pa

1.2 PBD 1.2from the

D5 PBD5: GDeclara

D8 PBD 8: of Conta

C CIPC/Cownershregistra

C Proof ofchanges

MI Licenceof the bCertifie

M Licenceannexurlisted onCertified

C Medicinall the aCertifiedNote: Abidder be sort

uirements an

ent Name

Declaration of

Certificate of ination

Authorisation Don-compliance

sation declaratvalidate the bid1: List of produrty

2: Unconditione third party.

Good Manufacation of complia

Special Requact. Declaratio

CIPRO or proofhip/shareholdition certificatef company ceds

e to manufactuidder), includ

ed copies req

e to manufactures for local mn the MRC of td copies requi

ne Registrationassociated cond copies

All MRC's muswith the releved and filed i

nd Conditions

f Past SCM Pr

Independent B

Declaration e to submissiotion, where apd. ucts offered so

nal written und

cturing Practicance.

irements and on of complian

f of ng. Certified c

es dings, mergers

ure or import (iing all annexuired.

ure medicines,manufacturinthe bidder (apred.

n Certificates (nditions of regi

st be marked vant item numn numerical o

s of Contract

ractices

Bid

on of a valid pplicable,

ourced from

ertaking

ce (GMP).

Conditions nce.

copies of

s and name

n the name ures.

including all g sites as

pplicant).

(MRC) with istration -

by the mber and order.

: HP06-2021

N/A Yes

SVP

Page 5 o

No

of 38

Remark

CompilaSequen

25

26

27

28

A

Submis

The bid

be com

“Set 3: E

S

ation nce

AdmCod

PI

PS

BL

PRIC

All bid docume

ssion of suppo

d document

mpleted by a

Electronic ve

Special Requ

min de

Docum

Originaldetailingthe MedSouth AAuthoritNote: Aitem numin nume

S Proof of

Bidder`s

CE Signed If the Exnot signnot be c

ents listed abo

orting bid docu

check list is

all bidders a

ersion of bid d

uirements an

ent Name

l Package Inseg professionaldicines ControAfrican Health ty (SAHPRA) f

All PI`s must bember and be serical order.

f sample subm

s item list (Lis

Excel Bid Resxcel Bid responed in the spacconsidered for

ove must be so

uments is com

s available a

nd be subm

documents"

nd Conditions

ert (PI) or docu information a

ol Council (MCProducts Regfor each produe marked with sorted and file

mission

st of products o

sponse Pricingonse Pricing Scce provided, thr evaluation.

orted, filed and

mpulsory, unlescolumn

as Annexure

mitted in hard

s of Contract

ument pproved by C) or the ulatory

uct offered. the relevant d/submitted

offered)

g Schedule chedule is he bid will

d submitted in

ss it's not appln

e A in an exc

d copy and

: HP06-2021

N/A Yes

the exact orde

icable and ind

cel spreadsh

as part of th

SVP

Page 6 o

No

er as indicated

dicated as such

heet format

he electroni

of 38

Remark

d above

h in the "N/A"

and should

c copies of

SECTIO 1. LEG

This

(Act

(Act

in te

are

Con

2. BID

As t

200

It is

allow

3. EVA

The

Ph

Mareq

Coand

S

ON A

GISLATIVE A

s bid and all co

t 101 of 1965)

t 194 of 1993)

erms of the Pu

supplementar

ntract are in co

D INFORMAT

the National D

2, published in

strongly reco

w the respons

ALUATION C

e evaluation pr

hase I

andatory and quirements

ompliance withd other bid req

Special Requ

AND REGUL

ontracts eman

, Pharmacy Ac

; General Con

ublic Finance M

ry to General C

onflict with the

TION SESSIO

Department of

n the Gazette

ommended tha

se to reach the

CRITERIA

rocess will be c

other bid

h mandatory quirements

uirements an

LATORY FRA

nating there fro

ct, (Act 53 of 1

nditions of Con

Management A

Conditions of C

General Cond

ON

Health complie

18 March 202

at all prospect

e bidders befor

conducted in p

Phase II

Product teccompliance

Compliance specificationTest reports sample evalu

nd Conditions

AMEWORK

om will be subj

1974); Patents

ntract issued in

Act, 1999 (Act

Contract (GCC

ditions of Cont

es with the reg

20 no briefing s

ive bidders su

re the tender c

phases as follo

chnical

with technical s received fromuation

s of Contract

ject to the Med

s Act, 1978 (Ac

n accordance

1 of 1999). Th

C). Where, how

tract, the Spec

gulations mad

session or pu

ubmit all enqui

closes.

ows:

Phase III

Price andB-BBEE

m

Bids evaluterms of thpreference

: HP06-2021

dicines and Re

ct 57 of 1978)

with Treasury

he Special Co

wever, the Spe

cial Conditions

e under the D

blic bid openin

ries to tenders

P

d Ran

uated in he 90/10 e system

Ran

SVP

Page 7 o

elated Substa

; Trade Marks

Regulation 16

onditions of Co

ecial Condition

s of Contract p

isaster Manag

ng will be held

[email protected].

hase IV

Recommendatnd Award

Recommendatind award

of 38

nces Act,

s Act, 1993

6A published

ontract (SCC)

ns of

prevail.

gement Act,

d.

.za on time to

tion

on

3.1

3.1.

S

PHASE I:

Bidders mu

and time of

documents

comply wit

.1 LEGISLA

Items offer

1965 (Act 1

contract.

A certified

the Medicin

items offer

The bidder

The bidder

in terms of

including a

the produc

The bidder

medicines,

also be the

Where an i

Related Su

Bidders mu

Marks Act,

Special Requ

MANDATOR

ust submit all r

f the bid. Durin

s submitted un

h all mandator

ATIVE REQUI

red must be re

101 of 1965),

d copy of the o

nes and Relat

ed.

r must be indic

r offering a pro

f section 22C (

all annexures.

ct.

r offering a pro

, including all a

e applicant.

item offered is

ubstances Act

ust comply wit

1993 (Act 194

uirements an

RY REQUIRE

required docum

ng this evalua

nder mandator

ry requiremen

IREMENTS T

egistered in ter

and must com

original Medici

ed Substance

cated as the ap

oduct must be

(1) (b) of the M

A certified co

oduct must sub

annexures for

s not eligible fo

, 1965 (Act 10

th the requirem

4 of 1993). Wh

nd Conditions

EMENTS

ments indicate

tion phase, bid

ry requirement

ts will be disqu

TO THIS BID

rms of section

mply with the co

ine Registratio

es Act, 1965 (A

pplicant on the

the holder of a

Medicines and

opy of the orig

bmit a certifie

local manufac

or registeration

01 of 1965), a p

ments of the P

here applicabl

s of Contract

ed above with

dder’s respons

ts. This phase

ualified.

D

15 of the Med

onditions of re

on Certificate,

Act 101 of 196

e Medicines R

a licence to m

Related Subs

ginal licence m

ed copy of the

cturing sites lis

n in terms of s

package inser

atents Act, 19

e, an explana

: HP06-2021

the bid docum

ses will be eva

is not scored

dicines and Re

egistration for t

issued in term

5), must be in

Registration Ce

anufacture or

stances Act, 19

must be submit

original licen

sted on the MR

ection 15(3) (a

rt of the item m

978 (Act 57 of

tion for any no

SVP

Page 8 o

ments at the cl

aluated based

and bidders w

elated Substan

the duration of

ms of section 1

cluded with th

ertificate.

import medici

965 (Act 101 o

tted by the bid

ce to manufac

RC of the bidd

a) of the Medic

must be supplie

1978) and the

on-compliance

of 38

osing date

on the

who fail to

nces Act,

f the

5(3) (a) of

he bid for all

ines issued

of 1965)

dder offering

cture

der who must

cines and

ed.

e Trade

e must be

3.1.

3.1.

3.1.

S

provided. I

holder of s

patent hold

.2 RESPONS

Bidders are

All prices

bid docume

Response

.3 BID DOCU

Bidders ar

and item q

The excel b

disability p

without cha

The prices

All prices

The bid pri

specificatio

Prices sub

VAT.

.4 AUTHOR

Only the ho

Substance

Special Requ

n the case wh

uch a product

der must be su

SIVE BIDS

e required to s

must be subm

ent. In this reg

Document” ex

UMENTS

e required to

uestionnaires.

bid response d

rovided forms

anging the stru

quoted must

must be subm

ce offered for

on and the unit

mitted must no

ISATION DE

older of a Med

s Act, 1965 (A

uirements an

here a product

, a letter autho

ubmitted with t

submit respons

mitted with 2

gard, bidder’s a

xplaining the d

submit respo

.

documents i.e

an integral pa

ucture thereof

be furnished a

mitted with tw

a product is d

t specified.

ot exceed the

ECLARATION

dicines Registr

Act 101 of 196

nd Conditions

is manufactur

orising the ma

the bid.

sive bids by co

(two) decima

attention is dra

different fields

nsive bids by

e. pricing sched

art of the bid d

. All pages mu

as all inclusive

wo (2) decima

deemed to be f

ex-manufactu

N

ration Certifica

5), may subm

s of Contract

red under a vo

rketing of the

ompleting all t

als. Documen

awn to the doc

in the bid docu

completing a

dule and Direc

ocument and

ust be signed.

e (incl. VAT) on

als.

for the pack si

urer componen

ate issued in te

it a bid.

: HP06-2021

oluntary licens

product, provi

he prices in th

nt and respons

cument “Defin

ument.

all the prices,

ctors: Categor

bidders must

n the basis of

ze as advertis

nt of the Single

erms of the Me

SVP

Page 9 o

e issued by th

ded to the bid

he Excel Bid R

se fields in the

ition of fields i

mandatory res

risation of race

ensure that it

supply and de

sed in the item

e Exit Price inc

edicines and R

of 38

he patent

der by the

Response.

e fillible PDF

n the Bid

sponse fields

e, gender and

is completed

elivery.

m

clusive of

Related

3.1.

S

In the even

external th

mutually ag

Where a th

Authorisati

The Nation

the Authori

Departmen

Failure to s

accordance

No agreem

Health.

.5 TAX COM

The Centra

the tax com

Certificates

Tax Cleara

It is a cond

satisfactory

It is a requ

an on-goin

submitting

Bidders are

their bid th

the supplie

Special Requ

nt that the Man

ird parties, the

greed upon be

hird party is inv

on Declaration

nal Departmen

isation Declara

nt of Health wi

submit a duly c

e with the abo

ment between t

MPLIANCE S

al Supplier Dat

mpliance statu

s anymore bu

ance Certificat

dition of this bid

y arrangement

irement that b

g basis during

this bid, such

e required to b

heir Master Re

er's tax status o

uirements an

nufacturer, Pa

e bidder must

etween the bid

volved in any c

n (PBD1) for e

nt of Health res

ation and, sho

ll exercise any

completed and

ove provisions,

the bidder and

STATUS

tabase and th

s of a bidder.

ut has introduc

tes which they

d that the tax m

ts have been m

idders grant a

g the tenure of

confirmation i

be registered o

egistration Nu

on the Centra

nd Conditions

cker or other e

ensure that al

dder and these

capacity, the b

each such third

serves the righ

ould the inform

y of the remed

d signed Autho

, will invalidate

d any third par

e tax complian

The South Afr

ced an online

y can submit w

matters of the

made with SA

a written confir

f the contract,

is deemed to h

on the Govern

umber (Supp

l Supplier Data

s of Contract

entity, as listed

l legal, financi

e third parties.

bidder must su

d party.

ht to verify any

mation be found

dies available t

orisation Decla

e the bid for su

rty will be bind

nce status PIN

rican Revenue

provision via

with their bids o

bidder be in o

ARS to meet th

mation when s

disclose the b

have been gra

nment's Centr

lier Number)

abase;.

: HP06-2021

d on the certifi

al and supply

ubmit a duly co

y information s

d to be false o

to it in the bid

aration, with th

uch goods or s

ing on the Nat

N are the appr

e Service doe

eFiling, for bid

or price quota

order at any po

he bidder’s tax

submitting this

bidder’s tax co

anted.

ral Supplier D

in order to ena

SVP

Page 10 o

icate of registr

arrangements

ompleted and

supplied by the

or incorrect, the

documents.

he required an

services offere

tional Departm

roved methods

s not issue Ta

dders to print

tions.

oint in time, or

obligations.

s bid that SAR

mpliance statu

Database and

able the institu

of 38

ration are

s have been

signed

e bidder in

e National

nnexure(s), in

ed.

ment of

s of verifying

ax Clearance

their own

r that

RS may, on

us and, by

to include in

ution to verify

4. PHA 4.1 SAM

All b

Dep

Fail

Sam

time

S

Foreign su

Africa mus

been made

Revenue S

Service wil

foreign ent

Should the

wull reject

The Nation

Where con

Supplier D

Bidders rem

this bid.

ASE II: PRO

MPLES TO B

bidders are req

partment of He

Compliance w

Compliance o

101 of 1965)

ure to submit

mples are requ

e of bid:

Special Requ

uppliers with

t complete th

e to a foreign b

Service to ema

ll issue a confi

tity has tax obl

e recommende

the bid submit

nal Departmen

nsortia/joint ve

atabase and t

main responsi

DUCT TECH

BE SUBMITT

quired to subm

ealth with prod

with specificat

of the product

.

samples at bo

uired to be sub

uirements an

neither South

he questionnai

bidder, the ND

ail address: G

irmation of tax

ligations in So

ed bidder fail t

tted by the bid

nt of Health sh

ntures/sub-co

heir tax compl

ble to update

HNICAL COM

TED TO HEA

mit samples, in

ducts to confirm

tions as set ou

t with the requ

oth health esta

bmitted to each

nd Conditions

h African tax

ire on the SB

DOH will subm

overnmentlnst

x obligations le

outh Africa

to provide writ

dder.

all verify the b

ntractors are i

liance status w

their CSD info

MPLIANCE

ALTH ESTAB

ncluding bidde

m the following

ut in the bid do

uirements of th

ablishments lis

h (both) of the

s of Contract

obligations n

D1. Where a

mit the bidder's

[email protected]

etter to the ND

ten proof of th

bidder’s tax co

nvolved, each

will be verified

ormation in line

BLISHMENTS

ers who are cu

g:

ocument/item s

he Medicines

sted below will

e addresses ind

: HP06-2021

nor history of

recommendat

s completed S

ov.za. The So

OH, confirmin

heir tax complia

mpliance statu

h party must be

through the C

e with the bid d

S

rrently supplyi

specification.

and Related S

invalidate the

dicated below

SVP

Page 11 o

doing busine

tion for award

BD1 to the So

uth African Re

ng whether or n

ance status, th

us through the

e registered o

Central Supplie

documents su

ing the Nation

Substances A

e bid for such it

prior to closin

of 38

ess in South

d of a bid has

outh African

evenue

not the

he NDOH

e CSD.

n the Central

er Database.

ubmitted for

al

Act, 1965 (Act

tems offered.

ng date and

Mr D

Dep

Tel:

Gau

Stor

35 P

Hurs

209

S

Dumisani Male

pot Manager

011 628 9131

uteng: Medical

re 3

Plunkett Avenu

st Hill

2

No samp

Samples

address.

Bidders

It is the

provided

All samp

All samp

All samp

approved

Proof of

evaluatio

Special Requ

ele

1

l Supplies Dep

ue

ples must be s

s must be ma

.

must submit a

responsibility

d above.

ples for awarde

ples must be a

ples submitted

d by the MCC

f sample sub

on site, must b

uirements an

pot

sent to the Nat

arked with the

at least one ori

y of the bidde

ed items will b

true represen

d must include

or SAHPRA.

mission, inclu

be submitted w

nd Conditions

tional Departm

e bid number,

iginal pack of e

er to ensure

e retained for

ntation of the p

e the package

uding a signe

with the bid do

s of Contract

Mr Nisaar M

Pharmaceut

Tel: 021 483

Western Ca

4th Floor, Ca

16 Chiappin

Cape Town

8001

ment of Health.

the item num

each offer for

that samples

the period of t

product which

insert or doc

ed copy of th

cuments at the

: HP06-2021

Mia

tical Policy Sp

3 5800

pe: Departme

ape Medical D

i Street

.

mber as well

evaluation.

have been r

the contract.

will be supplie

cument detailin

e item list as

e closing date

SVP

Page 12 o

ecialist

nt of Health

Depot

as the bidder

received at th

ed.

ng professiona

s received by

e and time of th

of 38

r’s name and

he addresses

al information

y the sample

he bid.

4.2 CO

Item 5. PHA 5.1 A M

5.2 PO

In te

awa

B-BCon

1

2

3

4

5

6

7

8

Non

For

S

MPLIANCE W

ms must compl

ASE IV: PRE

MAXIMUM OF

180Ps

Where Ps = Pt = Pmin =

INTS AWAR

erms of Regula

arded to a bidd

BEE Status Lentributor

-compliant cont

this tender, th

Special Requ

WITH SPEC

ly with the spe

EFERENCE P

F 80 OR 90 P

80/20

min

mi

P

PPt

Points scPrice of bPrice of l

RDED FOR B

ation 6(2) and

der for attainin

evel of

tributor

e 90/10 prefere

uirements an

IFICATIONS

ecification as d

POINT SYST

POINTS IS A

in

or

cored for pricebid under conslowest accepta

-BBEE STAT

7(2) of the Pr

g the B-BBEE

Number(90/10 sy

ence point sys

nd Conditions

S

detailed in the

TEM

ALLOCATED

or

90Ps

e of bid under csideration able bid

TUS LEVEL

referential Pro

E status level o

r of points ystem)

10

9

6

5

4

3

2

1

0

stem will be ap

s of Contract

bid document

D FOR PRICE

90/

m10

P

PPt

consideration

OF CONTRI

curement Reg

of contribution

plied.

: HP06-2021

t.

E ON THE FO

10

min

minP

BUTOR

gulations, prefe

in accordance

Number o(80/20 sys

SVP

Page 13 o

OLLOWING B

erence points

e with the table

of points stem)

20

18

14

12

8

6

4

2

0

of 38

BASIS:

must be

e below:

B

t

t

T

s

O

s

a

o

E

A

S

p

I

p

N

s

t

c

A

n

6. PRE

The

requ

In o

limit

med

prod

S

Bidders are re

the original B-

the B-BBEE st

The points sc

scored for pric

Only bidders w

submitted a c

accounting off

or an accredite

Exempted Mic

Affidavit as pre

Sworn Affidav

prescribed by

If the bidder f

preference po

National Depa

substantiate c

the nearest tw

contract will be

A contract ma

number of poin

EFERENCE

e National Dep

uired to indica

order to provide

ted to product

dicines (includ

duction of finis

Special Requ

equired to com

BBEE status l

tatus level poi

cored by a bid

ce.

who have com

certified copy

ficer (as conte

ed verification

cro Enterprise

escribed by th

vits submitted

the B-BBEE C

fails to compl

oints for B-BB

artment of H

claims it has m

wo (2) decima

e awarded to t

ay, on reasona

nts.

FOR LOCAL

partment of He

te on the Exce

e preference t

formulation an

ing importatio

shed products)

uirements an

mplete the pre

evel verificatio

nt.

dder in respec

mpleted and sig

of an origina

mplated in se

agency will be

es (EME’s) a

e B-BBEE Co

by EME’s an

Commission.

ly with the pa

BEE status lev

ealth may, b

made with rega

als. In the eve

the bidder sco

able and justif

LLY PRODU

ealth reserves

el Bid Respons

o locally produ

nd conversion

n of raw mate

) in the Repub

nd Conditions

eference claim

on certificate,

ct of the leve

gned the decla

al B-BBEE st

ction 60(4) of

e considered f

and Qualifying

ommssion, Pra

nd QSE will s

aragraphs abo

vel of contribu

before a bid

ard to prefere

ent that two (

oring the highe

fiable grounds

CED PRODU

the right to co

se Document

uced products

n processes th

rial of active p

blic of South Af

s of Contract

m form (SBD 6

at the closing

l of B-BBEE

aration part of

tatus level ce

the Close Cor

for preference

g Small Ente

actice Guide 01

strictly be eva

ove, the bidde

ution and will

is adjudicated

nce claimed.

(2) or more b

est number of p

s, be awarded

UCTS

onsider locally

where the pro

s, the definition

at use materia

pharmaceutica

frica.

: HP06-2021

6.1), and subm

date and time

contribution w

the preference

ertificate issue

rporation Act,

e points.

rprices (QSE

1 of 2019.

aluated accord

er will be dee

therefore be

d or at any

The points sc

bids have sco

preference po

d to a bid that

produced prod

oducts are man

n of a locally p

als and compo

al ingredients (A

SVP

Page 14 o

mit a valid cer

e of the bid in o

will be added

e claim form a

d by a regist

1984 (Act No.

’s) must sub

ding the the g

emed not to h

allocated a z

time, require

cored will be ro

red equal tota

ints for B-BBE

t did not score

ducts offered.

nufactured.

roduced produ

onents to manu

API) and of ex

of 38

rtified copy of

order to claim

to the points

and who have

tered auditor,

. 69 of 1984))

mit a Sworn

guidelines as

have claimed

zero (0). The

a bidder to

ounded off to

al points, the

EE.

e the highest

Bidders are

uct will be

ufacture

xcipients for

Whe

item

neg

Bids

7. VAL

All

bid

8. SUB

All b

indic

Sub

in th

All b

S

ere the Nation

ms will be alloc

gatively impac

s for products

The South A

primary site o

The bidder o

terms of sect

all annexures

The bidder of

including all a

applicant.

The referenc

The site/s of

Demonstrate

Excel Bid Re

Previous sup

Compliance t

LUE ADDED

bid prices mu

d.

BMISSION O

bid documents

cated below a

bmission of bid

he Bid Docume

bid documen

Special Requ

nal Departmen

cated and awa

ct upon secu

that qualify fo

African Health

of production a

ffering a prod

tion 22C (1) (b

s. A certified

ffering a produ

annexures for

e price as pub

manufacture a

d capacity to

sponse Docum

pplier performa

to all other asp

D TAX

st be inclusive

OF BIDS

s listed below m

and the annexu

d documents is

ent Check List

nts must be si

uirements an

t of Health giv

arded proportio

rity of supply

r this preferen

h Product Aut

as one that is l

uct must be th

b) of the Medic

copy of the o

uct must subm

r local manufa

blished by Nat

and/or packag

service the re

ment;

ance;

pects containe

e of 15% Value

must be sorted

ure attached.

s mandatory, u

t.

igned.

nd Conditions

ves preference

onately to loca

y and affordab

nce must comp

thority (SAHP

located in the

he holder of a

cines and Rela

original licence

mit a certified

acturing sites l

ional Departm

ging for the pro

equired volum

ed in these Sp

e-Added Tax.

d, filed and su

unless it's not

s of Contract

e to locally pro

ally produced p

bility.

ply with all of t

RA) certificate

Republic of S

licence to ma

ated Substanc

e must be subm

copy of the or

isted on the M

ment of Health

oduct offered is

mes as evaluat

ecial Conditio

Failure to com

ubmitted in the

applicable and

: HP06-2021

duced produc

products, prov

he following c

e of registrati

outh Africa;

anufacture or

ces Act, 1965

mitted by the b

riginal licence

MRC of the bid

has not been

s located in So

ted in terms o

ns of Contract

mply with this c

e exact compila

d indicated as

SVP

Page 15 o

cts, the quantit

ided this does

riteria:

ion for a prod

import medicin

(Act 101 of 19

bidder offering

to manufactur

dder who mus

exceeded (if a

outh Africa;

of the data pro

t

condition will in

ation sequenc

such in the "N

of 38

ies for these

s not

duct lists the

nes issued in

965) including

the product.

re medicines,

st also be the

applicable);

ovided in the

nvalidate the

ce as

N/A" column

Bidd

con

S

ders not com

sidered for ev

Covering Lett

Status relatin

Resolution/A

Bid/File Index

PBD 4.1: Con

SBD 1: Invita

Tax Clearanc

CSD Registra

be accepted;

SBD 4: Decla

PBD9: Direct

SBD5: The N

SBD 6(1): Pr

Valid B-BBEE

SBD 8: Decla

SBD 9: Certif

PBD1: Autho

where applica

PBD 1.1: List

PBD 1.2: Unc

PBD5: Good

PBD 8: Spec

CIPC/CIPRO

Proof of com

Certified copy

Certified copy

listed on the

Special Requ

plying to any

aluation.

ter i.e. limited

ng to TAX, B-B

uthority to sign

x;

ntact Details o

ation to bid;

ce Pin Issued;

ation report - A

aration of inter

tors: Categoris

National Indust

eference Poin

E certificate (c

aration of Past

ficate of Indep

orisation Decla

able, may inva

t of products o

conditional wri

Manufacturing

cial Requireme

O or proof of ow

pany cedings,

y of Licence to

y of Licence to

MRC of the bi

uirements an

y of the requi

stock availabi

BBEE, License

n bid;

of Bidder;

A certified cop

rest;

sation by race

trial Participati

nts Claimed (B

certified copy)

t SCM Practice

pendent Bid De

aration Note:

alidate the bid

offered sourced

itten undertaki

g Practice (GM

ents and Cond

wnership/share

, mergers and

o manufacture

o manufacture

dder (applican

nd Conditions

irements may

ility of any item

e to Manufactu

py of latest and

, gender and d

on Programm

-BBEE);

or Sworn Affid

es;

etermination;

Non-complian

;

d from third pa

ing from the th

MP). Declarati

itions of Conta

eholding. Cert

name change

e or import (in t

e medicines, in

nt);

s of Contract

y be deemed

m offered, non

ure, Certificate

d complete rep

disability;

e;

davit to claim p

ce to submiss

arty;

hird party;

on of complian

act. Declaratio

tified copies of

es;

the name of th

ncluding all an

: HP06-2021

to be non-re

-compliance;

es etc. Bid Sign

port. Note: CS

preference poi

sion of a valid

nce;

on of complian

f registration c

he bidder), inc

nnexures for lo

SVP

Page 16 o

esponsive and

nature;

SD summary r

ints;

d authorisation

ce;

certificates;

luding all anne

ocal manufactu

of 38

d will not be

report will not

n declaration,

exures;

uring sites as

9. CO

Bidd

mus

and

bid

info

Set

Bidd

field

copy

Bidd

Fina

S

Certified cop

(Annexure). N

filed in nume

Original Pac

Control Coun

product offe

filed/submitte

order;

Proof of sam

Bidder`s item

Signed Excel

Bid response

evaluation

MPLETION O

ders are requir

st be submitted

submitted in a

number and th

rmation reque

1: Hard copy

ders must com

d is provided b

y of the bid do

ders must sub

ancial Officer,

Special Requ

ies of Medicin

Note: All MRC

rical order;

kage Insert (P

ncil (MCC) or

red. Note: Al

ed in numerica

ple submissio

m list (List of pr

l Bid Respons

e Pricing Sch

OF DOCUME

red to submit t

d not later tha

a sealed pack

he closing date

ested is not rel

y legally bind

mplete all SBD

bidders must c

ocument will se

mit their comp

or authorised

uirements an

e Registration

C's must be ma

PI) or docum

r the South A

ll PI`s must

al

n;

roducts offered

se Pricing Sche

hedule is not

ENTS AND B

three sets of b

n the closing d

kage. The full n

e must be clea

evant this sho

ing bid docum

, PBD and Bid

omplete the fo

erve as the leg

plete bid in har

designee of th

nd Conditions

n Certificates (

arked by the b

ent detailing

African Health

be marked w

d); and

edule (All price

signed in the

BID SUBMIS

bid documents

date and time.

name and add

arly indicated o

ould be indicate

ments

d Response fo

orms in black i

gal bid docum

rd copy format

he entity subm

s of Contract

(MRC) with all

idder with the

professional i

h Products Re

with the relev

es must be su

e space provid

SION

s according to

. Set 2 and Se

dress of the bid

on the packag

ed with N/A.

orms in black in

nk, handwritte

ent.

t (paper docum

mitting the bid m

: HP06-2021

the associate

relevant item

information ap

egulatory Auth

vant item num

ubmitted in 2 (t

ded, the bid w

the instruction

et 3 must be in

dder, including

ge. All fields m

nk, typed. Whe

en in capital le

ment). The Ch

must sign the

SVP

Page 17 o

ed conditions o

number and b

pproved by th

hority (SAHPR

mber and be

two) decimals

will not be co

ns below. All th

ncluded on a C

g the return ad

must be comple

ere no electro

tters. The sign

hief Executive

official signatu

of 38

of registration

be sorted and

he Medicines

RA) for each

e sorted and

). If the Excel

onsidered for

hree sets

CD with Set 1

ddress, the

eted. Where

nic entry

ned hard

Officer, Chief

ure pages.

All p

not

As t

200

Bidd

Late

Bid

requ

two

unti

Set

Bidd

requ

Set

Bidd

Doc

All t

Bidd

unit

.

10. LAT

Bids

for c

S

pages in the co

acceptable. A

the National D

2, published in

ders must still

e bids will not

ders must ref

uested that b

o hole lever ar

ied for filing p

2: PDF of Ha

ders must sub

uested.

3: Electronic

ders must sub

cument and oth

three sets of in

ders must ens

pack as spec

TE BIDS

s received afte

consideration

Special Requ

omplete bid do

Any change/s m

Department of

n the Gazette

ensure that bi

be accepted fo

frain from us

bidders pre-pu

rch file. Bid d

purposes.

ard Copy, sign

mit a PDF ver

c version of b

mit the electro

her relevant s

nformation mu

sure that the p

cified. No conv

er the closing d

and, where pr

uirements an

ocument must

must be clearly

Health complie

18 March 202

ids are deliver

or consideratio

ing binding m

unch two hole

documents sh

ned legal doc

rsion of the en

bid documents

onic versions (

preadsheets in

st be submitte

rice quoted fo

version factors

date and time,

ractical, be ret

nd Conditions

t be initialed by

y indicated and

es with the reg

20 no briefing s

red on time to

on

methods like c

es on the left

hould be tied

cuments. (i.e.

tire signed ha

s

(editable pdf) o

n Excel (not pd

ed in order for

or a product (l

s will be applie

, at the addres

urned unopen

s of Contract

y same with b

d initialed.

gulations mad

session or pub

the correct ad

coil, comb, w

t hand side of

in parcels us

pdf of Set 1)

rdcopy bid, inc

of all SBD and

df).

the bid to be e

ine item) on th

ed.

ss indicated in

ed to the bidd

: HP06-2021

lack ink. The u

e under the D

blic bid openin

ddress and dep

wire velobind,

f bid docume

sing string or

cluding all cert

d PBD docume

evaluated.

he Bid Respon

the bid docum

er.

SVP

Page 18 o

use of correcti

isaster Manag

ng will be held.

posited in the

screw bindin

nts suitable f

rope that can

tificates and d

ents, Bid Resp

nse Document

ments, will not

of 38

ion fluid is

gement Act,

. However,

Tender Box.

ng etc. It is

for filing in a

n be easily

ocuments

ponse

t is for the

be accepted

11. CO

Bidd

con

12. FRO The

reco

them

com

The

part

accu

Guid

Indu

fron

bid/

sect

aga

13. SUP

The

any

the

14. CO

The

and

S

UNTER CON

ders’ attention

ditions by bidd

ONTING

e National Dep

ognises that re

mselves in acc

mpliant manner

e National Dep

t of the bid eva

uracy of the re

delines on Co

ustry, be estab

nting does not

contract and

tor for a period

inst the bidder

PPLIER DUE

e National Dep

time during th

site specified

MMUNICATI

e National Dep

time of the bi

Special Requ

NDITIONS

is drawn to th

ders may resu

partment of He

eal empowerm

cordance with

r. Against this

partment of He

aluation proce

epresentation

mplex Structu

blished during

exist. Failure t

may also resu

d not exceedin

r/contractor co

E DILIGENCE

partment of He

he contract pe

in the bid and

ION

partment of He

d and prior to

uirements an

he fact that am

lt in the invalid

ealth supports

ment can only b

the Constitutio

background, t

ealth, in ensuri

sses, conduct

made in bid do

res and Trans

such enquiry/

to do so within

ult in the restric

ng 10 years, in

oncerned.

E

ealth reserves

riod. This ma

the site comp

ealth, may com

the award of t

nd Conditions

mendments to a

dation of such

s the spirit of b

be achieved th

on and in an h

the National D

ng that bidder

t or initiate the

ocuments. Sh

sactions and F

/investigation,

n a period of 1

ction of the bid

n addition to an

the right to co

y include site

plies with quali

mmunicate with

the contract, o

s of Contract

any of the bid

bids.

road based bl

hrough individu

honest, fair, eq

Department of

rs conduct the

necessary en

ould any of the

Fronting, issue

the onus will b

4 days from d

dder/contracto

ny other reme

onduct supplier

visits to asses

ity criteria.

h bidders whe

or to extend the

: HP06-2021

conditions or

ack economic

uals and busin

quitable, transp

Health condem

mselves in an

nquiries/invest

e fronting indic

d by the Depa

be on the bidd

ate of notificat

or to conduct b

dies the Natio

r due diligence

ss whether an

re clarity is so

e validity perio

SVP

Page 19 o

setting of cou

c empowermen

nesses conduc

parent and leg

mns any form

honest mann

igations to det

cators as cont

artment of Trad

der/contractor t

tion, may inva

business with t

onal Treasury m

e prior to final

item is manuf

ught after the

od of the bid, if

of 38

nter

nt and

cting

gally

of fronting.

er will, as

termine the

tained in the

de and

to prove that

alidate the

the public

may have

award or at

factured at

closing date

f necessary.

Any

Dep

disc

All c

15. CO

Po

D

Pr

PR

00

Ple

S

y communicatio

partment of He

couraged.

communication

NTACT DET

ostal address

irectorate: Affo

rivate Bag X82

RETORIA

001

ease use the f

tenders@he

Special Requ

on to any gove

ealth in respec

n between the

TAILS

s

ordable Medic

28

following e-ma

ealth.gov.za

uirements an

ernment officia

ct of this bid be

e bidder and th

cines

ail address for

nd Conditions

al or a person

etween the clo

he National De

any queries re

s of Contract

acting in an a

osing date and

epartment of H

Physical ad

Directorate:

Civitas Build

242 Struben

Cnr Thabo S

Pretoria

0002

elating to bidd

: HP06-2021

advisory capac

the award of

Health, must be

ddress

Affordable Me

ding

Street

Sehume Street

ing process:

SVP

Page 20 o

city for the Nat

the bid by the

e done in writi

edicines

t

of 38

tional

bidder is

ng.

SECTI 16. C

T

17. P

P

N

P

O

18. R

A

af

F

S

ION B

CONTRACT P

he contract sh

PARTICIPATI

articipating Au

National Depar

rovincial Depa

Eastern Ca

Free State

Gauteng;

KwaZulu-N

Limpopo.

Other Institution

Nelson Ma

REGISTRATIO

All contracted s

fter award of c

ailure to meet

Special Requ

PERIOD

hall be for the

ING AUTHO

uthorities and

tments, Provin

artments:

ape;

;

Natal;

ns:

andela Children

ON ON DATA

suppliers must

contract.

this requirem

uirements an

period from 01

RITES AND

Health Establi

ncial Departme

ns' Hospital

ABASES OF

t register on th

ent will result

nd Conditions

1 May 2021 to

OTHER HEA

ishments whic

ents and orthe

F PARTICIPA

he supplier da

in the inability

s of Contract

o 30 April 2024

ALTH ESTAB

ch will be partic

er institutions a

Mp

No

No

W

ATING AUTH

atabases of Pa

to process pa

: HP06-2021

4.

BLISHMENT

cipating autho

as approved b

pumalanga;

orthern Cape;

orth West;

estern Cape; a

HORITIES

articipating Aut

ayment for goo

SVP

Page 21 o

S

orities in this co

by the account

and

thorities within

ods.

of 38

ontract are

ing officer.

n 30 days

o

19. P

R

P

A

en

of

20. A

T

sa

T

T

co

T

aw

In

D

pa

no

si

th

of 38

POST AWAR

Regulation 16A

ublic Entities,

Accounting Offi

ntity, request t

f state, subjec

AWARD CON

he National D

ame item.

he National D

he National D

ontractors (two

he following a

ward:

Source o

Capacity

Estimate

Risk to p

Past com

n cases where

Department of

ack sizes suita

o conversion f

izes during ev

hat specified is

Spe

D PARTICIP

A6.6 of the Tre

issued in term

icer/Accountin

to participate i

ct to the written

NDITIONS

epartment of H

epartment of H

epartment of H

o or more) to a

re examples o

of Active Pharm

y to meet expe

ed volume to b

public health if

mpliance of the

the tender do

Health reserve

able for a 28-d

factor will be a

aluation. Simil

s offered.

ecial Conditio

PATION

easury Regulat

ms of the Publ

ng Authority ma

n any contrac

n approval of s

Health reserve

Health reserve

Health reserve

address high v

of consideratio

maceuticaI Ing

ected demand

be supplied;

f the item is no

e bidder with c

oes not achiev

es the right no

day treatment

applied. Direct

larly, no conve

ons of Contra

tions for Depa

lic Finance Ma

ay, on behalf o

t arranged by

such organ of

es the right to

es the right to

es the right to

volume require

ons which may

gredient (API)

as per publish

ot available;

contractual obl

e the most eco

ot to award tha

cycle are requ

comparisons

ersion factors w

act: HP06-20

artments, Trad

anagement Ac

of a departme

means of a co

state and the

award contrac

negotiate price

award the sam

ements, secur

y be taken into

and actual ma

hed estimates

ligations.

onomically ad

at item. In the c

uired. Should a

will be made b

will be applied

021SVP

ing Entities, C

ct, 1999, (Act 1

nt, constitution

ompetitive bidd

relevant contr

cts to more tha

es.

me item as a m

rity of supply a

o account whe

anufacturing s

in the Excel B

vantageous p

case of medic

a 30-day or oth

between the 2

d in cases whe

Constitutional E

1 of 1999), sta

nal institution o

ding process b

ractors.

an one contrac

multiple award

and product av

n contemplatin

site;

Bid Response

rice, the Natio

ines for chron

her pack size

28-day and oth

ere a pack size

Entities and

ates that the

or public

by any organ

ctor for the

to various

vailability.

ng a multiple

Document;

onal

ic conditions,

be offered,

her pack

e other than

o

T

re

ite

an

th

T

H

ef

20.1 S

T

en

T

Tw

Categor

of 38

he National D

equired, due to

ems registered

nd time of bid

he contract for

he Departmen

However, in cas

ffect.

SPLIT AND M

he National D

nsure security

he following w

Source o

Capacity

Estimate

Risk to p

Past com

wo-way split a

ry

A

B

C

D

E

Spe

epartment of H

o emerging clin

d in terms of th

closure. In the

an item, or ad

nt of Health wi

ses where pat

MULTIPLE AW

epartment of H

y of supply.

will be taken in

of API and ma

y to meet expe

ed volume to b

public health if

mpliance of the

awards will be

ecial Conditio

Health may ch

nical evidence

he Medicines

ese circumstan

djust the quan

ll notify the co

tient safety is a

WARDS

Health reserve

to consideratio

nufacturing sit

ected demand

be supplied.

f the item is no

e bidder with c

made in acco

Differe

ons of Contra

hange treatme

e, disease prof

and Related S

nces, the Nati

tity awarded b

ontracted supp

a concern, the

es the right to

on when conte

te.

as per publish

ot available.

contractual obl

ordance with th

ence betweenscored

Equal points

< 5 points

>5-10 points

>10-20 points

>20 points

act: HP06-20

nt protocols a

files, safety or

Substances Ac

onal Departme

based on expe

plier within a re

ese changes m

issue split or m

emplating a sp

hed estimates

ligations.

he following sc

n points

s

021SVP

nd/or product

r resistance pa

ct, 1965, (Act 1

ent of Health r

ected changes

easonable time

may be implem

multiple award

plit award:

in the Bid Res

chedule based

Recommend

formulations w

atterns and ava

101 of 1965) a

reserves the ri

in projected d

e of the expec

mented with im

ds, where nece

sponse Docum

d on the points

ded percenta

50/50

60/40

70/30

80/20

90/10

where

ailability of

at the date

ight to cancel

demand.

ted change.

mediate

essary, to

ment.

s scored:

age split

o

20.2 T

T

d

t

c

a

t

f

T

S

m

f

c

m

w

S

a

o

of 38

Where a split

volumes for a

For a thr

For a fou

THERAPEUT

The Policy for

defines a thera

therapeutic eff

class, may diff

action, result i

these medicin

for a specific in

The ministeria

Standard Trea

mentioned in t

followed by an

classes have b

member of the

where appropr

Such therapeu

advantageous

offering the op

A single mem

Spe

t for more than

award:

ree way split: S

ur way split: Su

TIC CLASS A

Classifying M

apeutic class a

fects. Medicine

fer in chemistr

n different adv

es have close

ndication.

ally appointed

atment Guideli

the “Medicine

n example suc

been designat

e class for a sp

riate.

utic classes m

s contract, offe

pportunity for c

mber of the cl

ecial Conditio

n 2 suppliers is

Supplier share

upplier share =

AWARDS

Medicines into T

as a group of

es in a therape

ry or pharmaco

verse reaction

e similarity in e

National Esse

nes (STGs) an

treatment” sec

ch as, HMGCo

ted where non

pecific indicati

ay be used du

er the market t

cost efficiencie

lass may be a

ons of Contra

s contemplate

e = 33.3% + (s

= 25% + (supp

Therapetic Cla

medicines wh

eutic class ma

okinetic prope

s, have differe

efficacy and sa

ential Medicine

nd Essential M

ction of the na

oA reductase ih

ne of the memb

on. The NEML

uring the contr

he largest volu

es by stimulati

awarded.

act: HP06-20

ed, the followin

supplier score

plier score - m

asses for Purp

ich have active

ay or may not

erties, and may

ent toxicity and

afety profiles, w

es List Commit

Medicines List

ational STGs w

hibitors (Statin

bers of the cla

LC will designa

racting process

ume and incre

ng robust com

021SVP

ng formula may

- mean score)

mean score) x 2

poses of Thera

e ingredients w

belong to the s

y possess diffe

d drug interact

when administ

ttee (NEMLC)

(EML). Thera

which provides

ns) e.g. simava

ass offer any s

ate therapeuti

s to achieve th

ease the numb

mpetition.

y be used to a

) x 2.3%

2%

apeutic Interch

with comparab

same pharma

erent mechani

tion profiles. In

tered in equipo

formulates an

peutic classes

s a class of me

astatin. These

ignificant bene

c classes for a

he most econo

ber of competit

allocate

hange

ble

cological

isms of

n most cases,

otent doses

nd revises the

s are

edicines

therapeutic

efit over

a condition,

omically

tors, thereby

o

21 N

T

su

22. N

T

T

pr

In

re

23. P

T

co

ThC

Seri

of 38

NEGOTIATIO

he National D

uccessful bidd

NON-COMMIT

he National D

he right is also

rior to closing

n the event tha

emedy the ma

PRICE REVIE

he National D

ontract:

A routine a

An excepti

herapeutic lass and es Number Class 1

Class 2

Spe

ONS

epartment of H

der(s) post awa

TMENT

epartment of H

o reserved to w

of the bid and

at an incorrect

tter in any ma

EW

epartment of H

adjustment to m

onal adjustme

Therapeuticdescription

Surfactant - g

Surfactant - g

ecial Conditio

Health reserve

ard.

Health reserve

withdraw or am

d post award

award has be

nner it may de

Health envisag

mitigate foreig

ent to mitigate

c class

M

group 1 P

V

N

1

group 2 P

V

N

2

ons of Contra

es the right to

es the right no

mend any of th

een made, the

eem fit.

ges three type

n exchange flu

significant sho

Members of th

Phospholipids,

Vs

Natural Phosph

20mg in 1.5m

Phospholipids,

Vs

Natural Phosph

240mg in 3ml,

act: HP06-20

negotiate with

t to award, to

he bid conditio

National Depa

es of price revi

uctuations;

ort-term foreig

he therapeutic

Total (Beracta

holipids (Porac

ml, 1.5ml

Total (Beracta

holipids (Porac

3ml

021SVP

h the bidders p

award in part,

ons, by notice,

artment of Hea

ew processes

n exchange fl

c class

ant), 100mg/4

ctant alpha), in

ant), 200mg/8

ctant alpha), in

prior to award a

or in full.

in writing to a

alth reserves t

s for the duratio

uctuations; an

4ml, 1 Vial

ntra-tracheal s

8ml, 1 Vial

ntra-tracheal s

and with the

all bidders

the right to

on of this

nd

solution,

solution,

o

23.1 E

E

T

A

23.1.1 IN

23.2 P O

pr

A

of 38

A systemat

ELIGIBILITY R

ligibility for pri

he submission

Assessment of

NSTRUCTION

The price b

version. The

Active

Formu

Packa

Logist

Gross

The sum o

The local +

(e.g. Portio

component

VAT must

Labour mu

Breakdown

The Nation

component

RICE ADJUS

Only the portion

rice breakdow

Adjustments ar

Spe

tic review of p

RELATING T

ce adjustment

n of a complet

the rationality

NS FOR PRICE

reakdown mu

e delivered pri

Pharmaceutic

ulation;

aging;

ics (this includ

margin (rema

f these catego

+ imported por

on of API attr

t).

be apportione

ust be apportio

n must be in p

nal Departme

ts of the bid pr

TMENTS REL

n of the bid pri

wn on the signe

e always calcu

ecial Conditio

rices for comp

TO RATE OF

ts relating to fo

e price breakd

y of this price b

E BREAKDOW

st be complet

ce must be div

cal Ingredients

des transportat

aining portion).

ories must be e

rtions of the fi

ributable to loc

d equally acro

oned appropria

ercentage form

ent of Health

rice, which ma

LATING TO F

ice facing fore

ed bid submiss

ulated using th

ons of Contra

parable produc

F EXCHANG

oreign exchan

down per instru

breakdown by

WN

ted on the sig

vided across f

s (API);

tion, warehous

.

equal to 100%

rst three comp

cal + Portion

oss all compon

ately across th

mat to the clos

reserves the

ay include aud

OREIGN EXC

eign exchange

sion.

he original awa

act: HP06-20

cts available in

E ADJUSTM

nge risk depen

uctions below

the National D

ned bid respo

five componen

sing and distri

% of the deliver

ponents must

of API attribu

nents and not

e relevant com

sest whole per

e right to eng

dit of invoices a

CHANGE RISK

risk will be ad

arded contract

021SVP

n the internatio

MENTS

ds on:

for all relevan

Department of

onse documen

nts

bution);

red price for th

add up to 100

utable to impo

regarded as a

mponents.

rcentage (e.g.

gage with bid

and related do

K

djusted. This p

ted price as th

onal market pl

nt products; an

Health.

nt as well as t

he line item.

0% within eac

ort = 100% of

a separate com

20%).

dders to verify

ocumentation.

portion is deter

he base.

ace.

nd

the electronic

ch component

f specific API

mponent.

y any of the

rmined by the

o

P

ba

R

E

co

B

S

su

R

23.3 A

S

H

W

ad

F

Lo

of 38

rice adjustmen

ase average r

Rates are sourc

ligibility for fav

ompliance with

Base average

R

R

R

hould the bidd

ubmit the calc

Reserve Bank p

APPLICATION

canned copies

Health prior to t

Where no appli

djustment wou

oreign exchan

ogistics.

Spe

nts relating to

ate of exchang

ced from the R

vourable Contr

h contractual o

RoE for this t

Curren

Rand per US

Rand per Br

Rand per

Rand per Yuan

Rand per India

Rand per Dan

der make use

ulated averag

published rate

N FOR CONTR

s of signed ap

the submission

cation for an a

uld be favoura

nge adjustmen

ecial Conditio

foreign excha

ge (RoE) and

Reserve Bank

ractual Price A

obligations.

tender will be

cy

S Dollar

r Pound

Euro

Renminbi

an Rupee

ish Krone

of any currenc

e RoE for the

es for the spec

RACTUAL PR

pplications for

n dates detaile

adjustment rel

able to the Dep

nts may never

ons of Contra

ange will be ba

an adjustmen

(www.resbank

Adjustments m

e as follows, p

cy not mention

period 1 Janu

cific currency.

ICE ADJUSTM

price adjustme

ed in the table

ating to foreig

partment, this w

result in a pric

act: HP06-20

ased on the pe

t average RoE

k.co.za).

may be withdra

per currency:

Base Averagthe period

ned above, the

uary 2020 to 30

MENTS

ents must be r

es below.

n exchange ha

will be implem

ce exceeding t

021SVP

ercentage chan

E.

awn in light of e

:

ge Rates of Ex1 January 20

16.61

20.90

18.30

2.34

0.22

2.43

e bidder must s

0 June 2020 u

received by the

as been receiv

mented automa

the current Sin

nge between t

evidence of po

xchange Aver20 to 30 June

0

0

stipulate this c

using the Sout

e National De

ved and such

atically.

ngle Exit Price

the relevant

oor

rage for e 2020

clearly and

h African

partment of

an

e, ex

o

23.4 R

S

ta

Review

1

2

3

4

5

23.5 E

S

be

in

Review

0.1

1.1

2.1

3.1

4.1

5.1

of 38

ROUTINE PRIC

chedules for r

able below:

w Peadju

01 May

01 Nove

01 May

01 Nove

01 May

XCEPTIONAL

uppliers may r

e activated if t

ndicated in the

w Period

01

01 Nove

01

01 Nove

01

01 Nove

Spe

CE ADJUSTM

routine price re

eriod for calustment ave

y 2021 - 31 O

ember 2021 -

y 2022 - 31 O

ember 2022 -

y 2023 - 31 O

L PRICE ADJ

request excep

the absolute ch

table below fl

d for calculataverage

May 2021 -

ember 2021 -

May 2022 -

ember 2022 -

May 2023 -

ember 2023 -

ecial Conditio

MENTS

eviews, and pe

lculating erage RoE

October 2021

- 30 April 202

October 2022

- 30 April 202

October 2023

USTMENTS

ptional price ad

hange betwee

luctuates by m

ting adjustme RoE

31 July 2021

- 31 January

31 July 2022

- 31 January

31 July 2023

- 31 January

ons of Contra

eriods for calc

Subreque

reviewo

1 03 No

22 03

2 03 No

23 03

3 03 No

djustments acc

en the base Ro

more than 10%

ment Sre

rev

1 0

2022 03

2 0

2023 03

3 0

2024 03

act: HP06-20

ulating adjustm

bmission of est for procew to reach thoffice by

ovember 202

May 2022

ovember 202

May 2023

ovember 202

cording to the

oE and the thr

%.

Submission equest for prview to reach

office by

03 August 20

3 February 2

03 August 20

3 February 2

03 August 20

3 February 2

021SVP

ment average

e he

Daadjube

21 01

0

22 01

0

23 01

schedule in th

ree month retro

of roce h the

Dadb

021 01

2022

022 01

2023

023 01

2024

RoE are deta

ate from whiusted prices

ecome effect

December 2

01 June 2022

December 2

01 June 202

December 2

he table below

ospective ave

Date from wdjusted pricebecome effe

1 September

01 March 20

1 September

01 March 20

1 September

01 March 20

iled in the

ich s will tive

2021

2

2022

3

2023

w. These will

rage RoE

which es will ctive

r 2021

022

r 2022

023

r 2023

024

o

S

m

ad

Review

1

2

3

4

5

23.6 PR

Th

com

Wh

wil

Wh

rig

24. QU

Pro

Su

of 38

uppliers who r

months, rather

djustment ave

w Peadju

01 Augu

01 Feb

01 Augu

01 Feb

01 Augu

RICE ADJUST

e National De

mparable glob

here this revie

l enter into pri

here the outco

ht to terminate

UALITY

oducts must c

ubstances Act,

Spe

received exce

than the usua

erage RoE in th

eriod for calustment ave

ust 2021 - 31

bruary 2022 -

ust 2022 - 31

bruary 2023 -

ust 2023 - 31

TMENTS BAS

epartment of H

bal prices.

ew identifies an

ce negotiation

ome of this neg

e the award fo

onform to the

1965 (Act 10

ecial Conditio

ptional adjustm

al six month his

hese instance

lculating erage RoE

October 202

30 April 202

October 202

30 April 202

October 202

ED ON A SYS

ealth reserves

ny prices that a

ns with the con

gotiation is dee

or the item in q

conditions of

1 of 1965) for

ons of Contra

ments will rece

storical averag

s are detailed

Submisfor prreach

21 03 N

22 03

22 03 N

23 03

23 03 N

STEMATIC RE

s the right to re

are lower than

ntracted suppl

emed unfavou

uestion.

registration of

the full duratio

act: HP06-20

eive routine ad

ge exchange r

in the table be

ssion of reqroce review h the office

ovember 202

3 May 2022

ovember 202

3 May 2023

ovember 202

EVIEW

eview internat

n contract price

ier.

urable, the Nat

the product in

on of this cont

021SVP

djustments bas

rate. The perio

elow:

uest to by

Daadjube

21 01

0

22 01

0

23 01

ional prices to

es the Nationa

tional Departm

n terms of the

ract.

sed on the pre

ods for calculat

ate from whiusted prices

ecome effect

December 2

01 June 2022

December 2

01 June 202

December 2

o identify lowes

al Department

ment of Health

Medicines and

eceding three

ting

ich s will tive

2021

2

2022

3

2023

st

of Health

reserves the

d Related

o

25. DE 25.1 DE

Fir

Tra

Th

con

the

Le

by

cal

Fa

22

25.2 QU

Th

qu

Pro

Na

reg

Su

alig

of 38

ELIVERY AN

ELIVERY BA

rm lead times f

ansit and stora

e initial lead ti

ntract and NO

e date of awar

ad time within

the Departme

lendar days.

ilure to comply

of the Genera

UANTITIES

e quantities re

antity which w

oposed minim

ational Departm

garding MOQs

uppliers are req

gned with the

Spe

ND QUANTIT

ASIS

for delivery mu

age conditions

me as propos

OT the date of

rd.

the contract p

ent, as confirm

y with the con

al Conditions o

eflected in the

will be procured

um order quan

ment of Health

s cannot be re

quired to main

needs of Part

ecial Conditio

TIES

ust be quoted

s applicable to

sed in the bid r

placement of t

period is define

med by the Pro

tractual lead t

of Contract.

bid are estima

d during the co

ntities (MOQs

h reserves the

ached, the bid

ntain sufficient

icipating Autho

ons of Contra

for the duratio

the relevant p

response docu

the first order.

ed as the time

oof of Delivery

ime will result

ated quantities

ontract period.

) should facilit

right to negot

d may not be a

buffer stock to

orities.

act: HP06-20

on of the contr

products must

ument will be c

This period m

e from submiss

document. Th

in penalties b

s and no guara

. Fluctuations

tate delivery d

iate MOQs wh

awarded.

o meet at leas

021SVP

ract period.

be adhered to

calculated from

may not exceed

sion of order to

his lead time m

eing enforced

antee is given

in monthly de

irectly to healt

here necessar

st two-months

o.

m date of awar

d 75 calendar

o supplier to ti

may not exceed

as per paragr

or implied as

mand may occ

th establishme

ry. Where cons

demand for al

rd of the

days from

ime of receipt

d 14

raph 21 and

to the actual

cur.

ents. The

sensus

ll items,

o

SECTI 26. SU 26.1 Su

the

con

Na

Th

pe

of 38

ION C

UPPLIER PE

upplier perfor

e National Dep

ntractor and th

ational Departm

e National De

rformance of c

Compliance

As a minimu

mechanism

All trans

A mont

Product

Numbe

Numbe

Numbe

Status o

Attendance

The Na

not be

Supplie

efficien

The Particip

22 of the Ge

Non-complia

participation

Spe

RFORMANC

rmance mana

partment of He

he Participatin

ment of Health

epartment of H

contracted sup

e with reporting

um, suppliers

defined by the

sactional data

hly age analys

tion pipeline d

r of units of th

r of units of th

r of units of th

of outstanding

of compulsor

ational Departm

limited to, a

ers may be

cies in the sup

pating Authorit

eneral Conditio

ance of contr

n in future cont

ecial Conditio

CE MANAGE

gement will b

ealth and, whe

g Authority, N

h must be infor

ealth, in collab

ppliers in term

g requirements

will be require

e National Dep

relating to ord

sis;

data and foreca

e item availab

e item in Qual

e item in the c

g orders.

ry quarterly m

ment of Healt

review of su

required to p

pply chain to b

ties shall impo

ons of Contrac

racted supplie

tracts.

ons of Contra

EMENT

e the respons

ere supplier pe

ational Treasu

rmed for corre

boration with t

s of this contra

s according to

ed to submit th

partment of He

ders;

ast including:

ble (stock on h

lity Assurance

current month’

meetings

h will hold qu

upplier perform

present conti

benefit both su

ose penalties,

ct.

ers to the te

act: HP06-20

ibility of Partic

erformance dis

ury: Transvers

ective action.

he Participatin

act, including

o reporting sch

he following in

ealth:

and);

e, awaiting rele

s production p

arterly meetin

mance and fo

nuous improv

uppliers and th

where deeme

erms and con

021SVP

cipating Autho

sputes cannot

sal Contracting

ng Authorities,

but not limited

edule and rep

formation in a

ease;

plan.

ngs with suppl

orecasted dem

vement initiat

e Department

ed necessary,

nditions of thi

orities with ove

be resolved b

g Chief Directo

will monitor th

d to the followin

porting mechan

a specified form

iers which wil

mand for the

tives aimed

t of Health.

, as per Parag

is contract m

ersight from

between the

orate and

he

ng:

nism.

mat and via a

l include, but

next quarter.

at improving

graph 21 and

may influence

o

26.2 D

of 38

Contractors

order(s) as w

Contractors

and delivery

The instruct

invoices mu

orders issue

The Departm

quantity.

In order to f

orders for th

Only orders

Suppliers a

Authorities,

Changes to

The Particip

lead time sp

to the same

paragraph 2

In cases w

contracted s

DELIVERY AD

Products a

delivery ins

The inform

requiremen

Invoices m

particular m

Related Su

Spe

should note

well as for the

should note t

y points will be

tions appearin

ust be strictly

ed by the purc

ment of Health

facilitate efficie

he health estab

made using a

are required

in a manner s

any quantities

pating Authorit

pecified in the

e quantity in

21.6 of the Gen

here an orde

supplier must l

HERENCE

and related do

structions stipu

mation on invo

nts as defined

must reflect b

medicine, and

ubstances Act

ecial Conditio

that each in

payment(s) th

that the order

e specified by t

ng on the offi

adhered to an

hasing institut

h is under no

ent implement

blishment as p

an official, auth

to acknowled

stipulated by th

s ordered may

ties reserve th

contract and m

substitution o

neral Conditio

r is received

liaise with the

ocumentation

ulated on the p

oices and doc

by the Nation

oth the "prop

d which is the

t, 1965 (Act 1

ons of Contra

ndividual purc

hereof.

r(s) will be pla

the relevant p

icial order for

nd under no c

tions.

obligation to

tation of the d

per the purcha

horised purcha

dge receipt o

he relevant Pa

y only be made

he right to can

may, at their d

of the goods

ons of Contract

which appea

relevant Parti

must be deli

purchase orde

cuments relat

nal Departmen

prietary name

e name appro

01 of 1965), a

act: HP06-20

chasing institu

aced as and w

urchasing inst

m regarding t

circumstances

accept any qu

irect delivery s

ase order.

ase order form

of all purcha

articipating Aut

e upon receipt

ncel orders w

iscretion, purc

not supplied

t).

ars to be irrat

cipating Autho

ivered in acco

er.

ing to deliver

t of Health.

"(brand nam

oved in terms

and the item d

021SVP

ution is respo

when required

titution(s).

the supply, di

s should the c

uantity which i

strategy, contr

mat are valid.

se orders re

thority.

t of an amende

here the lead

chase supplies

in conformity

ional or misa

ority prior to pr

ordance with

ry must comp

me"/"trade nam

of section 15

description as

onsible for ge

during the co

ispatch and s

contractor dev

is in excess o

racted supplie

eceived from

ed purchase o

time exceeds

s of a similar q

with the con

aligned with e

rocessing the o

the terms, co

ply with the m

me") which is

5(4) of the M

s it appears in

enerating the

ontract period

submission of

viate from the

of the ordered

ers must pack

Participating

order.

s the delivery

quality and up

ntract (as per

stimates, the

order.

onditions and

minimum data

unique to a

Medicines and

n the contract

o

26.3 C

of 38

circular an

replace the

Original in

delivery po

may not be

know wher

The suppli

storage, as

receipt by t

Discrepanc

supplier wi

for the qua

Contracted

condition a

may recou

CONTINUITY O

Contracted

Contractor

Contractor

result in int

regula

any an

indust

challen

any ot

Contractor

as well as

Contractor

as well as

Spe

nd Master Pro

e MPC.

voices and p

oint. These do

e the same as

re documents

ier must ensu

s per product

the delegated

cies between

ithin a reasona

antities receive

d suppliers wil

as formally arr

p any expense

OF SUPPLY

d suppliers mu

s must mainta

s must inform

terrupted supp

atory action wh

nticipated prob

rial action

nges with man

ther supply cha

s must direct o

Participating A

s must direct

Participating A

ecial Conditio

ocurement Ca

proof of delive

cuments must

s the delivery a

must be delive

ure that produ

t's conditions

official.

invoice and p

able time or a

ed to be check

l be responsib

ranged in cons

es associated

ust have at lea

ain sufficient bu

National Dep

ply, including b

hich may impa

blems associat

nufacturing pip

allenges.

official commu

Authorities.

official commu

Authorities.

ons of Contra

talogue (MPC

ery must be a

t be delivered

address stipul

ered.

cts are delive

of registration

hysical stock,

as arranged w

ked upon recei

ble for collecti

sultation with t

with failure to

st two months

uffer stock thro

partment of He

but not limited

ct on their GM

ted with the av

peline;

unication relati

unication relat

act: HP06-20

C), or Master

authorised by

to the author

lated on the p

ered in accord

n. Delivery is

or damaged

ith the supplie

pt of delivery.

on of goods d

the purchasin

o collect such g

s' supply of the

oughout the d

ealth at first kn

to:

MP status or th

vailability of ac

ing to continuit

ting to paymen

021SVP

Health Produ

a delegated

ity responsible

purchase order

dance with the

deemed to te

stock, will be

er. This time p

delivered erron

g authority. Th

goods in accor

e estimate at th

uration of the

nowledge of a

hat of entities o

ctive pharmac

ty of supply to

nt challenges

uct List (MHPL

official at the

e for payment

r. Suppliers ar

e appropriate

erminate upon

reported to th

period must ma

neously, or in

he Participatin

rdance with th

he start of the

contract.

ny circumstan

on which they

eutical ingredi

o stockalert@h

to medacc@h

L), which will

e designated

. This may or

re required to

conditions of

signature of

he contracted

ake provision

the incorrect

ng Authorities

he agreement

contract.

nces that may

are reliant;

ient (API);

health.gov.za,

health.gov.za,

o

26.4 R

N

a

T

r

w

of 38

All official

ensure con

It is the res

items. In th

source alte

not more t

sourced fro

In the even

Health rese

duration of

Prior to th

submit the

4.The con

information

Name of th

The quanti

The period

The alterna

This provis

supply of th

Suppliers m

the Genera

In terms of

Participatin

urgently re

REPORTING

National Depa

assisted with c

The National

requirements.

writing by the

Spe

communicatio

ntinuity of supp

sponsibility of

he event that t

ernative produ

than three m

om another co

nt that a contr

erves the righ

f the contracte

he supply of a

e samples of t

ntracted suppl

n:

he product to b

ties to be supp

d for which the

ative product m

sion is only ap

he product.

may be require

al Conditions o

f the General C

ng Authorities

quired and is

artment of He

complying with

Department

Any changes

Directorate: A

ecial Conditio

on must includ

ply.

the contracted

the contracted

uct of accepta

onths. In the

ontracted supp

racted supplie

t to proportion

d supplier’s in

an alternative

the product to

lier is also re

be supplied;

plied;and

e product will b

must be suppl

pplicable for e

ed to pay pena

of Contract Pa

Conditions of

may purchase

not immediate

ealth will prov

h these require

of Health m

s to reporting

Affordable Med

ons of Contra

de detail of c

d supplier to e

d supplier is u

ble quality an

case of a m

plier for the sam

er is unable to

nally reallocate

nability to supp

product can b

o be supplied

equired to fu

be supplied.

ied at the curr

emergency su

alties for supp

aragraph 22.

Contract and

e outside the c

ely available.

vide the requir

ements.

ay, from time

requirements

dicines.

act: HP06-20

orrective actio

ensure continu

nable to supp

d up to the sa

multiple award

me product.

o supply in the

e volumes to a

ply.

be undertaken

to the two he

urnish the De

rent price of th

upply and can

ply exceeding

Special Requ

contract in ord

rements for re

e to time an

or the reporti

021SVP

ons taken by

uous availabilit

ply, the contrac

ame quantity

, the alternati

e short term, t

an alternative

n, the contrac

ealth establish

epartment of

e contracted it

nnot be used f

the contractua

irements and

der to meet its

eporting and

d within reas

ng mechanism

the contracte

ty and supply

cted supplier i

as required fo

ive product sh

he National D

contracted su

cted supplier i

hments as list

Health with t

tem.

for routine an

al lead time as

Conditions of

s requirements

successful bid

son, add to t

m will be com

ed supplier to

of contracted

id required to

or a period of

hould not be

Department of

upplier for the

s required to

ed in section

the following

d continuous

s stipulated in

Contract, the

s if the item is

dders will be

the reporting

mmunicated in

o

27. P

27.1 P

of 38

PACKAGING

PACKAGING

Suppliers

Packaging

Practice a

Packaging

adversely

The packa

acceptabl

The num

Documen

Where a

clearly illu

Where th

must be a

Oute

tamp

The c

when

Wher

be ad

Oute

tamp

The s

not a

The o

Spe

G, LABELLIN

must ensure

g must be su

and Good Dist

g must be su

y affect the sta

aging must be

le containers,

ber of units

nt.

particular stac

ustrated on the

e contents of

adhered to:

r packaging f

ering;.

contents must

n opened.

re the content

dhered to:

r packaging f

ering;.

shipper pack

llowed;.

outer packagin

ecial Conditio

NG AND BAR

e that product

itable for furth

tribution Practi

uitable for tran

bility and integ

e uniform for th

specifically de

per shipper p

cking and stor

e outer packag

the shipper p

flanges must

t be packed in

ts of a shipper

flanges must

must contain

ng must be cle

ons of Contra

RCODES

ts delivered a

her dispatch, s

ice.

nsportation an

grity of the pro

he duration of

eveloped for th

pack or origin

rage configura

ging.

pack represen

be sealed wi

n neat, uniform

r pack represe

be sealed wi

only one prod

early marked a

act: HP06-20

are received

storage and s

nd should pre

oduct.

the contract p

he product.

nal carton mu

ation is recom

t a standard s

th suitable ta

m rows and c

ent a non-stan

th suitable ta

duct, mixing of

as a "Part Box"

021SVP

in good orde

stacking accor

event exposur

period. All prod

ust be comple

mmended by th

supply quantit

ape that will c

columns that w

ndard supply q

ape that will c

f multiple prod

".

r at the point

rding to Good

re to condition

ducts must be

eted in the B

he supplier, th

ty of an item,

clearly display

will facilitate e

quantity, the fo

clearly display

ducts in a sing

t of delivery.

Wholesaling

ns that could

e packaged in

Bid Response

his should be

the following

y evidence of

easy counting

ollowing must

y evidence of

gle shipper is

o

27.2

27

of 38

2 LABELLI

All co

not le

The f

part b

I

o

R

N

B

E

S

B

Wher

e.g. t

indica

Unit p

in ter

includ

.3 BARC

All

Th

Su

the

Spe

NG

ontainers, pack

ess than font s

following infor

boxes:

tem name as

or Master Hea

Registered pro

Number of uni

Batch number

Expiry date;

Storage condit

Barcode.

re the contents

thermolabile, h

ated on the ou

packs must be

rms of the Me

de a barcode s

CODES

unit and shipp

e European A

ppliers are en

e following info

Item name

(MPC), or M

The "proprie

approved by

Dosage

Pack siz

ecial Conditio

kaging and ca

size 48.

rmation must

contained in t

alth Products L

oduct name (if

ts in pack

;

tions;

s of the shippe

high-scheduled

uter packaging

e labelled in a

edicines and

suitable for the

per packs mus

Article Numberi

ncouraged to i

ormation:

as contained

Master Health P

etary name (

y MCC or SAH

e form and stre

ze;

ons of Contra

artons must be

be clearly and

the contract ci

List (MHPL), w

f applicable);

er pack require

d or cytotoxic

g on a brightly

ccordance wit

Related Subs

e identification

st be marked w

ing Code 13 (E

include a 2D b

d in the contr

Products List (

(brand name"

HPRA;

ength;

act: HP06-20

e clearly labelle

d indelibly prin

ircular and the

which will repla

e special atten

products, suc

coloured back

th Regulation

stances Act, 1

n and tracking

with the appro

EAN 13) has b

barcode or sim

act circular a

(MHPL) which

"/"trade name

021SVP

ed. Bulk packs

nted on all sh

e Master Procu

ce the MPC.

ntion in terms

ch instructions

kground.

10 of the Gen

965 (Act 101

of medication

priate barcode

been accepted

milar on their

and the Maste

will replace th

”) unique to

s must be labe

hipper packs, i

urement Cata

of storage and

must be clear

neral Regulatio

of 1965). Th

.

e number and

d as standard.

packaging tha

er Procureme

he MPC.

a particular

elled in letters

including any

logue (MPC),

d/or handling,

rly and visibly

ons published

he label must

symbology.

at will include

nt Catalogue

medicine, as

o

28

29. CE Wh

a c

suc

Wh

sub

of 38

SHELF LIFE

Unless MCC

months upon

Contracted s

life provided t

Applicati

replaced

Applicati

Upon no

cost; and

Failure t

disposal

If short-date

will be appli

o A =

amo

disc

Unless othe

with a shelf-

EDING, MER

here a contrac

contract the co

ch an event.

here a contrac

bmit an officia

Spe

Batch n

Expiry d

E

or SAHPRA,

n delivery.

uppliers may a

that:

ions are accom

d or credited be

ions are appro

otification of re

d

to collect the

of the produc

ed products are

ed for invoicin

(12 – month

ount to be invo

count formula.

erwise agreed

-life of less tha

RGERS, TAK

cted supplier p

ontracted supp

cted supplier p

al request in wr

ecial Conditio

number;

date.

has approved

apply in writin

mpanied by an

efore or after e

oved by the Pa

emaining expir

products withi

ct by the Partic

e delivered wi

ng of short-date

s to date of e

oiced is: Cons

to, any Partic

an 12 months.

E OVERS AN

plans to merge

plier must infor

plans to cede a

riting to the ND

ons of Contra

d a shorter sh

g to Participat

n undertaking

expiry; and

articipating Au

red stock such

in 30 days aft

cipating Author

thout the afore

ed products:

expiry) x 2% x

signment value

cipating Autho

ND CHANGE

e with, or is go

rm the Nationa

a contrated ite

DOH, three mo

act: HP06-20

helf life, produ

ting Authorities

that such sho

thorities befor

h products will

ter written not

rity for the acc

ementioned un

x consignmen

e minus A, wh

ority may, with

ES IN SUPPL

ing to be acqu

al Department

m to another s

onths prior to t

021SVP

ucts must have

s to supply a p

ort-dated prod

re execution of

be collected b

tification to the

count of the su

ndertaking the

nt value short

here A is the v

hout prejudice,

LIER DETAIL

uired by, anoth

of Health in w

supplier, the c

the proposed

e a shelf-life o

product with a

ucts will be un

f orders; and

by the supplie

e supplier will

upplier.

e following disc

dated produc

value of the ou

, decline to ac

LS

her entity or pla

writing at first k

contracted sup

effective date.

of at least 12

a shorter shelf

nconditionally

r at their own

l result in the

count formula

ct. Therefore,

utcome of the

ccept product

ans to cede

knowledge of

plier must

.

o

Th

su

Th

unt

Th

ad

30. CAN Ca

sub

Th

unt

31. THIR

P

N

of 38

he NDOH rese

upplier under t

e contracted s

til such time th

e contracted s

dress, name,

NCELLATION

ancellation of

bmitted to the

e contracted s

til such time th

RD PARTIES

articipating Au

No third party is

Spe

erves the right

he prevailing c

supplier is obli

hat the NDOH

supplier must i

or contact det

N OF THE CON

a contract will

satisfaction o

supplier is obli

hat the NDOH

uthorities will n

s entitled to pu

ecial Conditio

to accept or d

conditions of c

ged to supply

has approved

inform the Nat

ails and effect

NTRACT

only be consi

f the Departm

ged to supply

has approved

not make a pa

ut an account o

ons of Contra

decline the req

contract or to c

the contracted

d the request t

tional Departm

t these change

idered after co

ent of Health.

the contracted

d the request t

yment to or co

of a Participat

END

act: HP06-20

quest to cede t

cancel the con

d item under t

to cede the ite

ment of Health

es on the Cent

ompelling evide

d item under t

to cancel the it

onsult with a th

ing Authority o

021SVP

the contractua

ntract.

he prevailaing

m to another s

at first knowle

tral Supplier D

ence to suppo

he prevailaing

tem.

hird party.

on hold.

al obligations to

g conditions of

supplier.

edge of any ch

Database.

ort the request

g conditions of

o the new

f contract,

hanges to

t has been

f contract,

ITEM LIST HP06-2021SVP

Item No DescriptionTherapeutic Class

NumbersUnit Estimate

1 Acetylcysteine 200mg/ml, injection, 10ml Each 213,295

2 Adenosine 3mg/ml, injection, 2ml Each 74,740

3 Adrenaline (Epinephrine) 0.15mg/0.3ml, auto-injection, 0.3ml Each 5,570

4 Adrenaline (Epinephrine) 0.3mg/0.3ml, auto-injection, 0.3ml Each 2,336

5 Adrenaline (Epinephrine) 1mg/ml, injection, 1ml Each 7,520,710

6 Alfentanil 0.5mg/ml, injection, 2ml Each 119,310

7 Alprostadil 0.5mg/ml, injection, 1ml Each 6,250

8 Alteplase 50mg, 1 Vial Each 7,960

9 Aminophylline 25mg/ml, injection, 10ml Each 354,560

10 Amiodarone 50mg/ml, injection, 3ml Each 223,660

11 Atracurium 10mg/ml, injection, 2.5ml Each 81,270

12 Atracurium 10mg/ml, injection, 5ml Each 58,400

13 Atropine 0.5mg/ml, injection, 1ml Each 1,278,840

14 Atropine 1mg injection, 1ml Each 2,353,110

15 Betamethasone 4mg/ml, injection, 1ml Each 1,199,860

16 Biperiden 5mg, injection, 1ml Each 63,180

17 Bupivacaine 5mg, Adrenaline 5mcg/ml, injection, 20ml Each 292,780

18 Bupivacaine 5mg, Dextrose Anhydrous 72.7mg/ml, injection, 4ml Each 974,370

19 Bupivacaine 5mg/ml injection, spinal, 4ml Each 206,140

20 Bupivacaine 5mg/ml, injection, 10ml Each 971,660

21 Caffeine 20mg/ml, injection, 1ml Each 185,250

22 Calcium gluconate 10% m/v, injection, 10ml Each 754,340

23 Cisatracurium 2mg/ml, injection, 2.5 ml Each 266,650

24 Cisatracurium 2mg/ml, injection, 5ml Each 237,390

25 Clonazepam 1mg/ml, injection, 1ml Each 514,285

26 Clotiapine 10mg/ml, injection, 4ml Each 78,395

27 Dantrolene 20mg, injection, 70 ml Each 2,280

28 Desferrioxamine 500mg, injection Each 49,970

29 Desmopressin 4mcg, injection, 1ml Each 9,660

30 Dexamethasone 4mg, injection, 1ml Each 5,270,300

31 Dexmedetomidine, 100 mcg/ml, Injection for infusion, 2ml Each 58,320

32 Dextrose 50% m/v, injection, 20ml Each 1,293,980

33 Dextrose 50% m/v, injection, 50ml Each 1,140,740

34 Diazepam 5mg/ml, injection, 2ml Each 771,330

35 Diclofenac 25mg/ml, injection, 3ml Each 8,327,390

36 Digoxin 0,25mg/ml, injection, 2ml Each 39,280

37 Dinoprost 5mg, injection, 1ml Each 900

38 Dobutamine 12.5mg/ml, injection, 20ml Each 206,440

39 Dopamine 40mg/ml, injection, 5ml Each 106,755

40 Enoxaparin 40mg, injection, 0.4ml Each 8,663,680

41 Enoxaparin 60mg, injection, 0.6ml Each 901,800

42 Enoxaparin 80mg, injection, 0.8ml Each 2,019,230

43 Ephedrine 50mg, injection, 1ml Each 325,270

44 Ergometrine 0.5mg, injection, 1ml Each 24,700

45 Erythropoietin 10 000 iu, injection, 0.6ml Each 88,800




Page 1 of 4





50 Etomidate 2mg/ml, injection, 10ml Each 145,080

51 Fentanyl 0.05mg/ml, injection, 2ml Each 1,581,570

52 Fentanyl 0.05mg/ml, injection, 10ml Each 370,850

53 Fluorescein 100mg/ml, injection, 5ml Each 1,536

54 Flupenthixol decanoate 20mg/ml, injection, 1ml Each 1,507,530

55 Furosemide 10mg/ml, injection, 25ml Each 245,280

56 Furosemide 10mg/ml, injection, 2ml Each 7,085,900

57 Furosemide 10mg/ml, injection, 5ml Each 342,230

58 Glucagon 1mg, injection, 1ml Each 30,050

59 Glyceryl trinitrate 1mg/ml, injection, 10ml Each 146,900

60 Glycopyrronium bromide 0.2mg/ml, injection, 2ml Each 622,200

61 Haloperidol 10mg/ml, injection, 2ml Each 24,220

62 Haloperidol 5mg/ml, injection, 1ml Each 447,790

63 Heparin 1000 iu/ml, injection, 5ml Each 693,310

64 Heparin 5000 iu/ml, injection, 5ml Each 946,240

65 Hydrocortisone 100mg/2ml, injection, 2ml Each 4,166,740

66 Hyoscine Butylbromide 20mg, injection, 1ml Each 2,338,110

67 Insulin analogue, Human, Long-acting, 100 u/ml, disposable pen, 3ml Each 33,860

68 Insulin analogue, Human, Ultrafast-acting 100 u/ml, disposable pen, 3ml Each 229,559

69 Insulin analogue, Human, Ultrafast-acting 100 u/ml, vial, 10ml Each 1,540

70 Insulin, Biosynthetic, Human, Isophane, 100 u/ml, disposable pen, 3ml Each 2,832,200

71 Insulin, Biosynthetic, Human, Isophane, 100 u/ml, vial, 10ml Each 903,640

72 Insulin, Biosynthetic, Human, Biphasic, 100 u/ml, soluble 30% and Isophane 70%, disposable pen, 3ml Each 11,488,740

73 Insulin, Biosynthetic, Human, Biphasic, 100 u/ml, soluble 30% and Isophane 70%, penfilll cartridge for use in

pens, 3ml

(PENS TO BE PROVIDED FREE OF CHARGE TO PATIENTS)

Each 2,188,000

74 Insulin, Biosynthetic, Human, Biphasic, 100 u/ml, soluble 30% and Isophane 70%, vial, 10ml Each 4,520,360

75 Insulin, Biosynthetic, Human, Soluble, 100 u/ml, disposable pen, 3ml Each 1,886,440

76 Insulin, Biosynthetic, Human, Soluble, 100 u/ml, vial, 10ml Each 387,840

77 Iron dextran containing elemental iron 50mg/ml, injection, 10ml Each 16,500

78 Iron dextran containing elemental iron 50mg/ml, injection, 2ml Each 211,350

79 Iron sucrose containing elemental iron 20mg/ml, injection, 5ml Each 271,550

80 Isulin analogue, Human, Ultrafast-acting 100 u/ml, penfill cartridge for use in pens, 3ml

(PENS TO BE PROVIDED FREE OF CHARGE TO PATIENTS)

Each 7,725

81 Ketamine 10mg/ml, injection, 20ml Each 96,930



84 Labetalol 5mg/ml, injection, 20ml Each 193,390

85 Lidocaine 1% m/v, injection, not for iv use, 20ml Each 1,821,100

86 Lidocaine 10% m/v, iv injection, 5ml Each 39,220

87 Lidocaine 2% m/v injection, not for iv use, 20ml Each 1,191,930

88 Lidocaine 2% m/v, Adrenaline 12.5mcg (1:80 000), dental cartridge, 1.8ml Each 18,119,370

89 Lidocaine 2% m/v, dental cartridge, 1.8ml Each 2,814,860

90 Lidocaine 2% m/v, iv injection, 5ml Each 1,964,420

91 Lorazepam 4mg, injection, 1ml Each 977,050

92 Magnesium sulfate 50%, injection, 2ml Each 5,111,040

93 Mannitol 25% m/v, injection, 50ml Each 19,320

94 Methylprednisolone 125mg, (as sodium succinate) injection, 2ml Each 33,765

Page 2 of 4






97 Methylprednisolone acetate 40mg/ml, injection, 2ml Each 257,150

98 Methylprednisolone acetate 40mg/ml, injection, 5ml Each 18,412

99 Metoclopramide 5mg/ml, injection, 2ml Each 7,601,990

100 Midazolam 1mg/ml, injection, 5ml Each 595,200



103 Morphine 10mg/ml, injection, 1ml Each 3,307,110

104 Morphine 15mg/ml, injection, 1ml Each 1,772,750

105 Naloxone 0.02mg/ml, injection, 2ml Each 96,540

106 Naloxone 0.4mg/ml, injection, 1ml Each 504,980

107 Natural Phospholipids (Poractant alpha), intra-tracheal solution, 120mg in 1.5ml, 1.5ml Class 1 Each 35,215

108 Natural Phospholipids (Poractant alpha), intra-tracheal solution, 240mg in 3ml, 3ml Class 2 Each 17,274

109 Needle, Insulin, 31G x 5mm, sterile, suitable for use with all prefilled insulin injection devices, 100 Each 82,770

110 Needle, Insulin, 31G x 8mm, sterile, suitable for use with all prefilled insulin injection devices, 100 Each 377,460

111 Neostigmine 0.5mg, injection, 1ml Each 107,590

112 Neostigmine 2.5mg, injection, 1ml Each 481,450

113 Octreotide 0.05mg, injection, 1ml Each 14,020

114 Octreotide 0.1mg, injection, 1ml Each 119,395

115 Octreotide 0.2mg/ml, injection, 5ml Each 8,380

116 Oxytocin 10 iu, injection, 1ml Each 6,406,260

117 Oxytocin 5 iu, injection, 1ml Each 2,063,960

118 Oxytocin 5iu, Ergometrine 0.5mg, injection, 1ml Each 538,290

119 Pantoprazole 40mg, injection, 10ml Each 1,042,800

120 Paracetamol 10mg/ml, injection for IV infusion, 100ml Each 1,585,240

121 Paracetamol 10mg/ml, injection for IV infusion, 50ml Each 6,910

122 Pethidine 25mg/ml, injection, 1ml Each 354,260

123 Pethidine 50mg/ml, injection, 1ml Each 1,815,320

124 Pethidine 50mg/ml, injection, 2ml Each 2,769,710

125 Phenylephrine 10mg, injection, 1ml Each 637,460

126 Phenytoin 50mg/ml, injection, 5ml Each 1,278,200

127 Phospholipids, Total (Beractant), 100mg/4ml, 1 Vial Class 1 Each 35,215

128 Phospholipids, Total (Beractant), 200mg/8ml, 1 Vial Class 2 Each 17,274

129 Potassium Chloride 15%, m/v injection, 10ml Each 2,470,180

130 Potassium Phosphate Monobasic, Anhydrous, Potassium Phosphate Dibasic Anhydrous, 1.09g/1.05g,

injection, 10ml

Each 131,090

131 Promethazine 25mg/ml, injection, 1ml Each 691,430

132 Promethazine 25mg/ml, injection, 2ml Each 319,811

133 Propofol 10mg/ml, injection, 20ml Each 1,446,630

134 Propofol 10mg/ml, injection, 50ml Each 195,590

135 Protamine 10mg/ml, injection, 5ml Each 52,140

136 Quinine 300mg, injection, 1ml Each 46,610

137 Ranitidine 25mg/ml, injection, 2ml Each 822,410

138 Remifentanil 2mg, injection, 5ml Each 47,070

139 Rocuronium 50mg, injection, 5ml Each 777,100

140 Salbutamol 0.5mg, injection, 1ml Each 301,240

141 Sodium bicarbonate 4% m/v, injection, 50ml Each 109,550

Page 3 of 4




142 Sodium bicarbonate 8.5% m/v, injection, 50ml Each 578,010

143 Sodium chloride 0.9% m/v, injection, 10ml Each 12,400,540

144 Somatropin 15iu, powder for injection, cartridge + diluent Each 23,720

145 Somatropin 30iu, powder for injection, cartridge + diluent Each 24,895

146 Somatropin 36iu, powder for injection, cartridge + diluent Each 426

147 Streptokinase 1.5MU injection Each 10,155

148 Suxamethonium 50mg/ml, injection, 2ml Each 635,010

149 Testosterone 1g injection, 1 injection Each 16,415

150 Thiopentone 0.5g, injection, 20ml Each 23,540

151 Tramadol 50mg/ml, injection, 2ml Each 3,207,480

152 Tranexamic Acid 100mg/ml, injection, 5ml Each 1,734,980

153 Vecuronium 4mg, injection, 2ml Each 53,840

154 Verapamil HCl 2.5mg/ml, injection, 2ml Each 17,910

155 Vitamin B Complex, injection, 10ml Each 429,600

156 Vitamin B1 (Thiamine) 100mg/ml, injection, 10ml Each 412,200

157 Vitamin B12 (Cyanocobalamin) 1000mcg, injection, 1ml Each 487,350

158 Vitamin K1 (Phytomenadione) 10mg/1ml, injection Each 773,990

159 Vitamin K1 (Phytomenadione) 2mg/0.2ml, injection Each 3,500,390

160 Water for injection BP, injection, 10ml Each 37,241,680

161 Water for injection BP, injection, 20ml Each 4,112,500

162 Zuclopenthixol acetate 50mg, injection, 1ml Each 228,680

163 Zuclopenthixol decanoate 200mg/ml, injection, 1ml Each 2,142,750

Page 4 of 4

ADDENDUM 1: REPLACEMENT OF VERSION 1 CONTRACT …

Documents

Transcript of ADDENDUM 1: REPLACEMENT OF VERSION 1 CONTRACT …